| Excerpt | Reference |
|---|
| "The role of chemotherapy in colorectal cancer is still not precisely defined." | ( Rauchenberger, B; Winkler, R, 1977) |
| "The evolution of metastatic colorectal cancer in patients who have had surgical treatment for a primary lesion was studied in relation the progressive changes in the blood levels of carcinembryonic antigen (CEA), to gamma glutamyl transpeptidase (GGT) and routine liver function tests (LFTs)." | ( Cooper, EH; Mackay, AM; Neville, AM; Steele, L; Turner, R, 1975) |
| "A group of 24 patients with colorectal cancer and another group of 28 patients with 13 different primaries were treated." | ( Minton, JP; Petrek, JA, 1979) |
| "Forty-six adult patients with colorectal cancer were treated with cyclophosphamide and CCNU administered orally and 5-fluorouracil (5-FU) administered either orally or by continuous iv infusion (FCC-CIF), depending on the availability of hospital beds." | ( Bedikian, AY; Bodey, GP; Burgess, MA; Livingston, R; Staab, R; Valdivieso, M, 1978) |
| "Fifty-two untreated patients with colorectal cancer were randomized to receive 5-fluorouracil (5-FU) alternating either with methotrexate (MTX) or Baker's Antifol (BAF) with or without the immunostimulant, levamisole (Program I)." | ( Bedikian, AY; Bodey, GP; Burgess, MA; Mavligit, GM; Rodriguez, V; Valdivieso, M, 1978) |
| "Four patients with primary inextirpable rectal cancer and 10 patients with locally recurrent rectal cancer have been treated." | ( Hafström, L; Jönsson, PE; Landberg, T; Owman, T; Sundkvist, K, 1979) |
| "Fifty-two patients with advanced colorectal cancer were treated with a combination of 5-Fluorouracil (FU) plus methyl-1,3-cis (2-chlorethyl)-1-nitrosourea (MeCCNU)." | ( Frei, E; Lokich, JJ; Mayer, RJ; Skarin, AT, 1977) |
| "A series of 84 cases of rectal cancer treated in this way is reported." | ( Fazio, VW; Kirwan, WO; Turnbull, RB; Weakley, FL, 1978) |
| "Prolifirative activity of rectum cancer cells was investigated with the help of 3H-thymidine in 13 patents before and after radiotherapy in doses 2000-4000 rad." | ( Gapaniuk, ON; Zagrebin, VM, 1976) |
| "Palliative treatment of recurrent rectal cancer remains to be a challenge." | ( Kolotas, C; Kuhn, FP; Schmitt, G; Schnabel, T; Zamboglou, N, 1992) |
| "Five colorectal cancer patients with nonresectable metastatic liver cancer underwent continuous intraarterial chemotherapy in our institute from January to December 1991." | ( Kubota, Y; Masaki, T; Ooya, M; Sakaguchi, M; Sameshima, S; Sawada, T; Shinozaki, M; Tsuno, N; Uchiyama, M; Watanabe, T, 1992) |
| "Twelve colorectal cancer patients, including 9 with local recurrent cancer and 3 with remnant cancer after surgery, were treated with intraarterial chemotherapy." | ( Hashimoto, M; Hosoda, Y; Katai, H; Koh, J; Maeda, K; Murayama, Y; Sakai, S; Sano, M; Suzuki, K; Yamamoto, O, 1992) |
| "Eleven patients with rectum cancer and four patients with colon cancer were treated according to the following schedule: 9 million units IFN-alpha subcutaneous three times a week; 500 mg/m2 5-FU via an intravenous bolus 1 hour after the initiation of a 2-hour infusion of 500 mg/m2 of FA, once a week." | ( Bernhard, H; Klein, O; Knuth, A; Meyer zum Büschenfelde, KH, 1992) |
| "Several trials in rectal cancer show an advantage for 5-FU combined with semustine and radiation therapy in terms of disease-free survival, overall survival, or both; the contribution of semustine has been questioned and is currently being investigated." | ( Grem, JL, 1991) |
| "A case of local recurrence of rectal cancer was successfully treated by UFT combined with two-route CDDP chemotherapy under the AT-II induced hypertension." | ( Ishizawa, T; Iwashige, H; Maenohara, S; Mure, H; Shimazu, H; Takao, S; Yamada, K, 1991) |
| "A total of 38 cases of advanced rectal cancer (non-radiation group; 25 cases, radiation group; 13 cases) was studied in order to clarify the effect of preoperative radiation therapy (42." | ( Inoue, I; Nakayama, H; Nunomura, M; Okui, K; Saitoh, N; Sarashina, H, 1991) |
| "Between 1980 and 1987, 25 patients with rectal cancer were treated with a combination of preoperative external irradiation of 35 Gy in 15 fractions over 3 weeks which was followed, 6 to 8 weeks later, by a tumorectomy and peroperative placement of a plastic tube loop for post-operative interstitial therapy by iridium-192." | ( Calitchi, E; Despretz, J; Grimard, L; Julien, M; Le Bourgeois, JP; Mazeron, JJ; Otmezguine, Y; Pierquin, B, 1989) |
| "Five cases of rectal cancer, one male and 4 females, were preoperatively treated with Tegafur suppositories at 1,500 mg per day, for 8 to 21 days (mean, 14 days)." | ( Konn, M; Mikami, K; Morita, T; Ono, K; Yamanaka, Y; Yoshiwara, S, 1989) |
| "A 68-year-old male, who had advanced rectal cancer with multiple pulmonary metastases, had undergone resection of rectal cancer operatively and was treated with a combination chemotherapy using 5'-DFUR (5'-deoxy-5-fluorouridine) and MMC (mitomycin C) for multiple pulmonary metastases." | ( Baba, K; Kawano, H; Matsuda, M; Matsuoka, Y; Morinaga, H; Nagao, K; Nagase, H; Nishimura, R; Ueno, Y, 1989) |
| "Conservative procedures to treat rectal cancer are also gaining support because of reduced morbidity and mortality, avoidance of colostomy, and excellent survival figures in selected patients." | ( Curley, SA; Rich, TA; Roh, MS, 1989) |
| "Twelve patients with advanced colorectal cancer were subjected to alternating cycles of treatment with low immunomodulating doses of recombinant alpha-interferon (alpha IFN) + 5-fluorouracil (5FU) or with 5FU alone." | ( Bonmassar, E; Bonmassar, G; Cucchiara, G; De Vecchis, L; Lagomarsino Caprino, M; Nunziata, C; Picconi, A; Ricci, F, 1989) |
| "Following coloscopic diagnosis of colorectal tumors treatment was administered twice weekly for a 10-week period." | ( Berger, MR; Garzon, FT; Keppler, BK; Schmähl, D, 1987) |
| "Sixty-six patients with advanced colorectal cancer were treated with 5-fluorouracil, Mitomycin C, and 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea." | ( Chapman, J; Chinn, B; Demitrish, MM; Enochs, K; Garland, M; Groshko, G; Pederson, B; Rocchio, R; Vaughn, CB; Ward, D, 1986) |
| "The group of research for colorectal cancer treatments-Kajitani-group (chief T." | ( Hojo, K; Kajitani, T, 1986) |
| "Ten patients with rectal tumors were treated by surgical excision of the tumor using a CO2 laser Sharplan 733 CO2 laser, Laser Industries Ltd." | ( Merhav, H; Pfeffermann, R; Rothstein, H; Simon, D, 1986) |
| "Thirty-eight colorectal cancer patients (pts) with metastatic liver cancer who underwent intra-arterial infusion chemotherapy (IAIC) at the National Cancer Center Hospital from May 1986 to April 1988 were reviewed." | ( Hojo, K; Moriya, Y; Sawada, T, 1988) |
| "Forty patients with colorectal cancer metastatic to the liver were treated with an implanted pump for hepatic artery perfusion." | ( Johnson, LP; Rivkin, SE, 1985) |
| "Twenty-three patients with advanced colorectal cancer were treated with folinic acid (200 mg/m2/day 1-5 IV bolus injection) and 5-fluorouracil (400 mg/m2/day 1-5 IV in 15 minutes) every 28 days." | ( Bartolucci, R; Brugia, M; Buzzi, F; Di Costanzo, F; Padalino, D, 1988) |
| "Fifty-five patients with advanced colorectal cancer were entered into a randomized controlled clinical trial to evaluate order of administration and sequential methotrexate (MTX) and 5-fluorouracil (5-FU) therapy." | ( Coates, A; Mackintosh, J; Raghavan, D; Swanson, C; Tattersall, MH, 1987) |
| "Fifteen patients with colorectal tumors underwent external scintigraphy following the administration of 5." | ( Abdel-Nabi, HH; Higano, CS; Schwartz, AN; Unger, MW; Wechter, DG, 1987) |
| "Following curative surgery for colorectal cancer 141 patients were randomized to receive a 6 month course of 5-fluorouracil (5FU) with or without postoperative levamisole or supportive treatment only." | ( Bell, PR; Shaw, D; Windle, R, 1987) |
| "The results of combined treatment for rectal cancer including preoperative intraarterial chemotherapy are discussed." | ( Mel'nikov, RA; Mosidze, BA, 1988) |
| "Thirty-six patients with advanced colorectal cancer with unequivocal evidence of progression while treated with fluoropyrimidines were treated with a six-day continuous infusion of 500 mg/m2/d of folinic acid initiated 24 hours before a five-day course of 5-FU administered as an intravenous (IV) bolus of 370 mg/m2/d." | ( Bertrand, M; Blayney, DW; Carr, BI; Cecchi, G; Doroshow, JH; Goldberg, D; Leong, L; Margolin, K; Metter, G; Multhauf, P, 1986) |
| "Eighteen adult colorectal cancer patients, previously untreated with systemic chemotherapy, were given CCNU and MISO." | ( Anagnost, J; Bennett, JM; Boros, L; Mulcahy, RT; Siemann, DW; Sutherland, RM, 1987) |
| "Multimodality therapy for colorectal cancer is composed of surgery, chemotherapy and irradiation; and hyperthermia joins them recently." | ( Fujimoto, S; Miyazaki, M; Okui, K, 1985) |
| "Thirty-six patients with advanced colorectal cancer whose disease progressed during treatment with 5-fluorouracil (5-FU) chemotherapy were treated with methyl-CCNU and methotrexate." | ( Bazos, MJ; Evans, WK; Myers, R; Shepherd, FA; Zorzitto, ML, 1986) |
| "Twenty-nine patients with advanced colorectal cancer were treated with methotrexate (MTX) 200 mg/m2 followed 1 h later by fluorouracil (FU) (1000 mg/m2) and 24 h later by oral leucovorin 20 mg every 6 h for six doses." | ( Ford, J; Margolese, R; Panasci, L, 1985) |
| "Treatment of colorectal cancer beyond surgical resection has had only minimal success in the past." | ( Muggia, FM, 1985) |
| "Sixteen patients with advanced colo-rectal cancer were treated with the combination methyl-CCNU, vincristin, 5-fluorouracil and streptozotocin (MOF-Strepto)." | ( Cavalli, F; Sessa, C; Togni, P; Varini, M, 1982) |
| "Patients with advanced colorectal cancer and no prior chemotherapy were randomized to six treatment regimens: A) fluorouracil (FU) alone; B) FU + hydroxyurea (HU); C) semustine (SE) + dacarbazine (DA); D) FU + HU alternating with SE + DA; E) SE + razoxane (RA); F) mitomycin (MI) + DA." | ( Engstrom, PF; Klaassen, DJ; MacIntyre, JM; Mittelman, A, 1984) |
| "Three hundred and eleven cases of rectal cancer received treatment according to the protocol of a cooperative randomized study." | ( Aliev, BM; Barsukov, IuA; Bondar', GV; Dvoĭrin, VV; Knysh, VI, 1984) |
| "One case of survived rectal cancer obtained disease-free for about 8 years with this treatment." | ( Kai, Y; Kaiyama, H; Kanazawa, Y; Nakano, N; Okata, T; Sasaki, K; Shoji, T; Takeda, T; Tiba, J; Ujie, S, 1984) |
| "Three rectal cancer patients with partial response (PR) were obtained by oral administration of 800-1200 mg/day of SF-SP." | ( Endo, S; Furukawa, R; Katsumi, S; Mukae, S; Sato, T; Sekine, S; Watanabe, I; Watanabe, S, 1984) |
| "No excess mortality from noncolorectal cancers was apparent, nor were there significant differences by treatment: TSPA (22/22), FdUrd (9/12), and surgery only (50/42)." | ( Boice, JD; Fraumeni, JF; Greene, MH; Higgins, GA; Keehn, RJ, 1980) |
| "It is concluded that some colorectal cancers can be treated as hormone-sensitive tumors." | ( Hoppen, HO; Izbicki, JR; Izbicki, W; Schmitz, R; Troidl, H, 1984) |
| "Among 16 evaluable patients with colorectal cancer (three of whom had received prior chemotherapy), there were no objective responses." | ( Calman, KC; Crossling, F; Ferguson, C; George, WD; Habeshaw, T; Hutcheon, A; Kaye, SB; McArdle, C; Sangster, G; Smith, D, 1984) |
| "Twenty-two patients with advanced colorectal cancer were treated with 10-deaza-aminopterin given intravenously twice weekly for four doses beginning at 15 mg/m2." | ( Cheng, EW; Currie, VE; Yagoda, A, 1983) |
| "Two patients with advanced rectal cancer, women aged 73 and 49 years, have survived more than nine years with chemotherapy only and no surgical removal of the disease foci." | ( Fukuda, I; Iwanaga, T; Koyama, H; Otani, T; Taniguchi, H, 1981) |
| "Less than 20% of advanced colorectal cancers respond to chemotherapy." | ( Balint, JA; Van der Veer, LD, 1980) |
| "46 patients with rectal cancer were treated preoperatively with intrarectal administration of 5-FU emulsion (25 cases) or 5-FU suppositories (21 cases) for a period of 10 days before surgery, and the histological effect of this regimen on the metastatic lesion in the lymph nodes, as well as in the primary tumor was examined." | ( Fijita, Y; Kojima, O; Majima, S; Morisawa, K; Nishioka, B; Umehara, M; Watanabe, S; Yamane, E, 1980) |
| "Twenty patients with rectal cancer were treated with combined chemoradiation prior to operation, after pretreatment staging of all lesions with transrectal ultrasound (TRUS)." | ( Blatchford, GJ; Christensen, MA; Meade, PG; Ternent, CA; Thorson, AG, 1995) |
| "In the treatment of stages 2 and 3 rectal cancer, significant reductions in local recurrence and death rates have been achieved with the combination of 5-fluorouracil and radiation therapy." | ( Sinicrope, FA; Sugarman, SM, 1995) |
| "10 patients with advanced colorectal cancer were treated with elevated doses of carmustine and mitomycin C." | ( Codacci Pisanelli, G; Franchi, F; Giovagnorio, F; Gualdi, G; Guazzugli Bonaiuti, VP; Seminara, P, 1994) |
| "For Dukes' B2 and C rectal cancer, standard therapy is postoperative treatment with fluorouracil-based chemotherapy and concurrent pelvic radiotherapy." | ( Ilson, DH; Kelsen, DP, 1994) |
| "51 patients with metastatic colorectal cancer (stage Dukes D) were treated with intravenous (i." | ( Dünser, E; Essl, R; Fritz, E; Mascher, H; Micksche, M; Sagaster, P; Teich, G; Umek, H; Wasilewski, M, 1994) |
| "Fifty-seven Dukes C colorectal cancer patients were given 5-fluorouracil-interferon-alpha 2b adjuvant treatment from October 1986 to September 1990." | ( Cremone, L; Espinosa, A; Faiella, F; Frasci, G; Leone, F; Monaco, M; Persico, G; Sapio, U, 1994) |
| "Patients with resectable rectal cancer, both those who are node positive and those with tumor extending to the serosa (Dukes' B2) are appropriately treated with a combination of postoperative radiation therapy and chemotherapy, the latter given for 6 months." | ( Marsh, JC, 1994) |
| "Thirty-one patients with fixed rectal cancers (stage > or = cT3) were treated with concomitant preoperative chemotherapy and high-dose radiation in an effort to improve resectability." | ( Brodovsky, H; Chen, ET; Fishbein, G; Marks, G; Mohiuddin, M, 1994) |
| "Combined modality treatment for cancer of the rectum has been shown to reduce recurrences and improve overall survival." | ( Ackland, SP; Bonaventura, A; Cooper, SG; Denham, JW; Hamilton, CS; Joseph, DJ; Stewart, JF, 1993) |
| "Failure rate of colorectal cancer after surgical resection remains around 50% and adjuvant treatments are clearly required." | ( Nordlinger, B; Rougier, P, 1993) |
| "Thirty-five patients with rectal cancer underwent surgery after this treatment, and 41 patients underwent surgery without pretreatment." | ( Ichikawa, D; Sawai, K; Takahashi, T; Yamaguchi, T; Yoshioka, Y, 1996) |
| "In the majority of patients with rectal cancer invading perirectal tissues or lymph nodes, lesions may be downstaged by preoperative adjuvant therapy." | ( Bernini, A; Deen, KI; Madoff, RD; Wong, WD, 1996) |
| "To identify appropriate candidates with rectal cancer for preoperative chemoradiation therapy, the local recurrence rate and clinicopathological characteristics of 232 patients with rectal cancer undergoing curative resection in our department were investigated." | ( Iihara, K; Kimura, M; Kitada, M; Murotani, M; Niinobu, T; Nose, T; Ogawa, M; Shibata, T; Takada, T; Takami, M; Tsujinaka, T; Tsukahara, Y; Tsukamoto, F, 1996) |
| "Resection of colorectal cancer and portal infusion of adjuvant chemotherapy." | ( , 1997) |
| "Three rectal cancer patients were treated with arterial infusion chemotherapy through the internal iliac artery." | ( Aoyama, H; Fukunaga, T; Imazeki, H; Isono, K; Iwasaki, K; Maeda, T; Matsuzaki, H; Miyazaki, S; Nakajima, K; Okazumi, S; Shinotou, K; Shutou, K; Takayama, W; Takeda, A, 1997) |
| "In patients with resectable rectal cancer, randomized trials reveal an improvement in local control and survival with postoperative combined modality therapy." | ( Minsky, BD, 1997) |
| "Fifty-five colorectal cancer patients who had continuous intraportal chemotherapy between 1990 and 1993 (treated group) and 130 colorectal cancer patients who did not have portal chemotherapy between 1982 and 1993 (untreated group) were studied to clarify the effects of continuous intraportal chemotherapy on the prognosis." | ( Adachi, W; Amano, J; Kajikawa, S; Koide, N; Koike, S; Kuroda, T; Mihara, M; Nakata, S; Watanabe, H; Yazawa, K, 1998) |
| "Treatment of colorectal cancers is based on surgery and the prognosis is determined by the locoregional or metastatic tumor spread." | ( Bours, V; Fillet, G; Jerusalem, G, 1998) |
| "Data from 12 metastatic colorectal cancer patients who were submitted to a pilot study with a multistep subcutaneous (sc) low dose recombinant interleukin-2 (rIL-2), 5-fluorouracil (5-FU) and leucovorin (LV) administration were compared with those from 13 historical controls who were comparable for the major prognostic indices." | ( Anselmi, L; Carpi, A; Ferrari, P; Nicolini, A; Sagripanti, A, 1998) |
| "However, a rapidly growing invasive rectal cancer developed in one of 15 patients with sulindac-treated sporadic adenomatous colorectal polyps 16 months after sulindac treatment." | ( Matsuhashi, N; Nakajima, A; Oka, T; Shinohara, K; Yazaki, Y, 1998) |
| "Patients with resectable rectal cancer who received 20 Gy/5 fractions preoperative radiotherapy to the pelvis had excellent local and distant control of disease." | ( Birnbaum, E; Fleshman, J; Fry, R; Genovesi, D; Kodner, I; Lockett, MA; Menteer, J; Myerson, RJ; Picus, J; Read, T; Walz, B, 1999) |
| "All patients had metastatic colorectal cancer, with adjuvant or palliative chemotherapy given to six patients (22%) on schedule A and 12 patients on schedule B (41%)." | ( Adam, R; Bismuth, H; Dallemagne, B; Focan, C; Focan-Henrard, D; Jasmin, C; Jehaes, C; Kreutz, F; Levi, F; Lobelle, JP; Markiewicz, S; Misset, JL; Weerts, J, 1999) |
| "We report a 68-year-old man with rectal cancer and recurrent pulmonary metastasis treated with concomitant 5'-DFUR + MMC, which resulted in an extreme reduction of the lesion." | ( Aihara, S; Hiki, Y; Ishikawa, H; Kakita, A; Kanazawa, H; Ohtani, Y, 1999) |
| "When disseminated colorectal cancer is diagnosed the possibility of palliative chemotherapy should be conferred with an oncologist." | ( Raskov, HH; Wiboltt, K, 1999) |
| "Despite of improvement of results in rectum cancer treatment after systematical introduction of total mesorectal excision as a standard procedure to control the compartment disease, surgical radicality may be limited in cases with large tumours in ventral position because of eccentric location of the rectum in the perirectal fat." | ( Fasolini, F, 1999) |
| "Ten patients diagnosed with rectal cancer received 250 U/kg of recombinant human erythropoietin subcutaneously three times per week during preoperative radiation and chemotherapy." | ( Hambrick, E; Laborde, C; Levine, EA; McKnight, CA; Vijayakumar, S, 1999) |
| "Sixty-six patients with colorectal cancer were studied regarding effects of prevention of hepatic recurrence in completely performed portal infusion chemotherapy." | ( Akaishi, O; Tsukikawa, S; Yabe, K; Yamaguchi, S; Yamamura, T, 1999) |
| "Recurrent colorectal cancers respond poorly to anticancer treatment including radiotherapy." | ( Chung, EJ; Kim, GE; Kim, H; Kim, NK; Min, JS; Seong, J; Sohn, SK; Suh, CO, 1999) |
| "We report a case of unresectable rectal cancer in a 53-year-old male treated with chemoradiation." | ( Musha, N; Oka, K; Saito, H; Sando, N; Sasaki, M; Setu, M; Setu, Y; Sunami, E, 2000) |
| "Thirty-three patients with fixed rectal cancers were treated with combined 5-fluorouracil (5-FU) chemotherapy and pelvic radiation." | ( Hagihara, PF; John, WJ; Kenady, DE; Marks, G; McGrath, PC; Mohiuddin, M; Regine, WF, 2000) |
| "Patients with primary rectal cancer deemed eligible for preoperative radiation and 5-fluorouracil-based chemotherapy because of a clinically bulky or tethered tumor or endorectal ultrasound evidence of T3 and/or N1 were prospectively enrolled." | ( Akhurst, T; Cohen, AM; Erdi, Y; Finn, RD; Gollub, MJ; Guillem, JG; Humm, J; Klimstra, DS; Larson, S; Macapinlac, H; Mazumdar, M; Minsky, BD; Paty, PB; Puig-La Calle, J; Ruo, L; Saltz, L; Tickoo, S; Yeung, H, 2000) |
| "Standard adjuvant chemotherapy for colorectal cancer consists of fluorouracil with folinic acid or levamisole." | ( , 2000) |
| "The regimen appears active against rectal cancer, and appears to warrant further consideration as a treatment option for this patient population." | ( Anscher, MS; Dewhirst, MW; Hurwitz, H; Jowell, P; Lee, C; Prosnitz, LR; Rosner, G; Samulski, T; Tyler, D, 2000) |
| "In locally advanced rectal cancer, pre-operative chemo-radiotherapy had a low toxicity profile." | ( Cameron, F; Dewar, J; Einhorn, S; Elsaleh, H; Joseph, D; Latham, M; Levitt, M; Osborne, M; Robbins, P; Van Hazel, G, 1999) |
| "Advanced colorectal cancer has traditionally been treated with 5-fluorouracil, alone or in combination with leucovorin." | ( Harboe, K; Lind, A; Ogreid, D; Todnem, K; Zotova, L, 2000) |
| "Patients with locally advanced operable rectal cancer (uT3/4 or uN+, Mason CS III/IV) were randomly assigned to pre- or postoperative radiochemotherapy: A total dose of 50." | ( Becker, H; Fietkau, R; Hess, C; Hohenberger, W; Jatzko, G; Karstens, JH; Martus, P; Raab, R; Rödel, C; Sabitzer, H; Sauer, R; Wittekind, C, 2001) |
| "Pretreatment stages of the rectal cancer were T3, 89% and resectable T4, 11%, with endorectal ultrasound confirmation in 67% of patients." | ( Bell, A; Burmeister, BH; Fisher, R; Goldstein, D; Joseph, D; Kneebone, A; MacKay, JR; Ngan, SY; Rischin, D; Schache, DJ, 2001) |
| "114 patients with rectal cancer were treated by selective preoperative intra-arterial infusion chemotherapy." | ( Li, J; Liu, F; Qi, X, 2000) |
| "This treatment induced apoptosis of rectal cancer cells and inhibit tumor cell proliferation." | ( Li, J; Liu, F; Qi, X, 2000) |
| "Ten patients with invasive distal rectal cancer (six T2, four T3) were treated with preoperative radiotherapy (3600-5040 cGy) with or without 5-fluorouracil based chemotherapy." | ( Cohen, AM; Guillem, JG; Minsky, BD; Paty, PB; Quan, SH; Ruo, L, 2002) |
| "Patients with hepatic metastases from rectal cancer treated with hepatic artery (HA) chemotherapy have a life expectancy great enough to be at risk for pelvic failure." | ( Andrews, JC; Cha, C; Ensminger, WD; Lawrence, TS; Robertson, JM, 1996) |
| "During adjuvant radiotherapy (RT) for rectal cancer, patients receiving 5-fluorouracil (5-FU) by protracted venous infusion have a higher risk of diarrhea than have patients receiving bolus 5-FU." | ( Cha, SS; Gunderson, LL; Haller, D; Macdonald, JS; Martenson, JA; Mayer, RJ; Miller, RC; O'Connell, MJ; Rich, TA; Sargent, DJ, 2002) |
| "Thirty-six patients with rectal cancer received treatment in the adjuvant, neoadjuvant, or palliative setting with a total irradiation dose of 50." | ( Dunst, J; Frings, S; Hinke, A; Kölling-Schlebusch, K; Reese, T; Sutter, T; Zühlke, H, 2002) |
| "We treated a patient with unresectable rectal cancer with multiple liver, pulmonary and lymph node metastases that responded remarkably to pharmacokinetic modulating chemotherapy (PMC)." | ( Chiba, M; Hayashi, K; Inaba, Y; Kamio, Y; Koyama, M; Ohe, S; Watabe, S, 2002) |
| "In the management of rectal cancer after the combined therapy of the radiation and surgical operation, the evaluation of the prognosis is important." | ( Abe, A; Kumakura, Y; Momose, T; Nakagawa, K; Ohtomo, K; Oku, S; Watanabe, T, 2002) |
| "Forty patients with rectal cancer in the lower rectal region underwent two series of FDG-PET study before and after pre-operative radiotherapy." | ( Abe, A; Kumakura, Y; Momose, T; Nakagawa, K; Ohtomo, K; Oku, S; Watanabe, T, 2002) |
| "Generally, patients with advanced rectal cancer in whom surgical treatment is contraindicated receive radiation or chemotherapy." | ( Fujiyama, J; Fukuda, K; Hagiwara, A; Ito, T; Itoi, H; Kin, S; Kitamura, K; Nakase, Y; Okamoto, K; Otsuji, E; Sakakura, C; Shimomura, K; Takagi, T; Toma, A; Yamagishi, H, 2002) |
| "In patients with locally advanced rectal cancer located 3-6 cm from anal verge who are traditionally treated with abdominoperineal resection, preservation of anal sphincter after preoperative chemoradiation therapy plus complete rectal excision with coloanal anastomosis is feasible and is associated with acceptable morbidity and no mortality." | ( Fernández, R; Gutiérrez De La Barrera, M; Hernández-Pacheco, F; Labastida, S; Luna-Pérez, P; Rodríguez-Ramírez, S, 2003) |
| "Adjuvant radiation therapy for rectal cancer is not widely used in Japan, while chemotherapy is considered the adjuvant treatment of choice." | ( Kakeji, Y; Kohnoe, S; Maehara, Y, 2002) |
| "Initial treatments of locally advanced rectal cancers focus on local control, as local relapse of a rectal cancer is correlated with a high morbidity and mortality." | ( Hospers, GA; Mulder, NH; Reerink, O; Szabo, BG; Verschueren, RC, 2003) |
| "Fifty patients of rectal cancer diagnosed by pathological examination were randomly divided into two groups, 35 in the treated group and 15 in the control group." | ( Chen, YQ; Ji, MX; Xing, JH, 2001) |
| "The standard in rectal cancer has been to add adjuvant radiation therapy to surgery in patients with stage II and III disease." | ( Bechtel, J; Tepper, J, 2003) |
| "Adjuvant therapy of rectal cancer follow the progress obtained in colon cancer using adjuvant fluorouracil based chemotherapy and is also based on radiotherapy." | ( Bouaouina, N; Boussen, H, 2003) |
| "The local recurrence rate of colorectal cancer has been significantly reduced due to the use of combined radiochemotherapy." | ( Abdel-Rahman, S; D hmke, E; Ertl-Wagner, B; Issels, RD; Krych, M; Pachmann, S; Schaffer, M; Schaffer, PM, 2003) |
| "Records of surgically resected rectal cancer patients who underwent FDG-PET imaging at least 6 months after external beam radiation therapy (EBRT) were reviewed." | ( Akhurst, T; Guillem, JG; Larson, SM; Mazumdar, M; Minsky, BD; Moore, HG, 2003) |
| "Peripheral lymphocytes of twelve rectal cancer patients who had undergone postoperative radiochemotherapy 2-3 years ago were investigated for residual chromosomal damage using 24-color fluorescence in situ hybridization (24-color FISH)." | ( Claussen, U; Dreidax, M; Dunst, J; Kuechler, A; Liehr, T; Pigorsch, SU; Wendt, TG, 2003) |
| "The study reviewed Stage II and III rectal cancer patients treated with preoperative chemoradiation and resected for cure." | ( Blatchford, GJ; Brown, CL; Christensen, MA; Haynatzki, GR; Shashidharan, M; Ternent, CA; Thorson, AG, 2003) |
| "Twenty-five male rectal cancer patients (mean age 65 years), receiving pelvic radiation therapy (2 Gyx23-25 fractions in 5 weeks) were included." | ( Dueland, S; Guren, MG; Magne Tveit, K; Olsen, DR; Poulsen, JP, 2003) |
| "Radiation therapy (46-50 Gy) for rectal cancer resulted in a significant increase in serum FSH and LH and a significant decrease in testosterone levels, indicating that sex hormone production is sensitive to radiation exposure in patients with a mean age of 65 years." | ( Dueland, S; Guren, MG; Magne Tveit, K; Olsen, DR; Poulsen, JP, 2003) |
| "The treatment of colorectal cancer with administration of a 2-h infusion of calcium folinate followed by a 24-h infusion of 5-fluorouracil (5-FU) is a standard therapy." | ( Bruch, HR; Esser, M, 2003) |
| "We report a rectal cancer case with liver and lung metastases treated successfully with this protocol." | ( Ebuchi, M; Hasegawa, K; Kato, K; Maruyama, M; Nagahama, T; Shinoura, H; Takashima, I, 2003) |
| "A 46-year-old female with rectal cancer who had undergone operation and subsequent adjuvant chemotherapy two years previously was referred to our department for a follow-up whole body FDG-PET study." | ( Fang, CL; Hsu, CH; Lee, CM; Wang, FC, 2003) |
| "In stage II (T3-4N0) and III (TxN1-2) rectal cancer, adjuvant radiochemotherapy improves overall survival and decreases the rate of local failure compared to only surgical therapy and is regarded as standard for patients with carcinoma of the lower and intermediate rectum." | ( Folprecht, G; Köhne, CH, 2004) |
| "Adjuvant therapy of colorectal cancer with oral fluorinated pyrimidines is attractive because of its ease of administration and good tolerability." | ( Burzykowski, T; Buyse, M; Hamada, C; Ohashi, Y; Piedbois, P; Sakamoto, J, 2004) |
| "In the majority of patients with rectal cancer invading perirectal tissues or lymph nodes, lesions downstages by preoperative chemo radiotherapy." | ( Juska, P; Pavalkis, D; Pranys, D, 2004) |
| "A total of 145 rectal cancer patients were treated with surgery and postoperative radiochemotherapy." | ( Berger, J; Heide, J; Krüll, A, 2004) |
| "One hundred and fifty-five rectal cancer patients undergoing preoperative pelvic external beam radiation therapy and 5-fluorouracil-based chemotherapy followed by rectal resection were identified." | ( Gittleman, AE; Guillem, JG; Minsky, BD; Moore, HG; Paty, PB; Saltz, L; Shia, J; Temple, L; Weiser, M; Wong, D, 2004) |
| "Patients with advanced colorectal cancer were treated with 5-FU [bolus (400 mg/m(2)) followed by a 22-h infusion (600 mg/m(2))] and LV (200 mg/m(2)) and escalating doses of SAM486A, 1-3-h infusion daily for 3 days." | ( Bootle, D; Bridgewater, J; Choi, L; de Bruijn, P; Eskens, FA; Ledermann, JA; Mueller, C; Planting, AS; Sklenar, I; Sparreboom, A; van Zuylen, L; Verweij, J, 2004) |
| "Preoperative chemoradiotherapy in rectal cancer using chronomodulated 5-FU and LV is feasible." | ( Berry, S; Bjarnason, GA; Davey, P; de Marsh, RW; Mendenhall, W; Parulekar, W; Rout, WR; Wong, R; Zlotecki, R, 2004) |
| "We treated 2 patients with colorectal cancer accompanied by liver metastasis who showed favorable response to combined treatment with fluorouracil and l-Leucovorin." | ( Aoki, T; Ichimiya, H; Kato, K; Katsumata, K; Okada, K; Wakana, Y, 2004) |
| "Adjuvant therapy for colorectal cancer has been one of the most important contributions of medical oncology to the health of the population, saving more lives annually than more effective therapy for less common cancers, such as Hodgkin's disease." | ( Cohen, SM; Neugut, AI, 2004) |
| "In resectable rectal cancer, if preoperative treatment is considered, this approach can be an option." | ( Almenar, D; Aparicio, J; Arlandis, F; Bosch, C; Campos, J; Campos, JM; Climent, MA; Estevan, R; Fernández-Martos, C; Garcera, S; Hernandez, A; Maestu, I; Mengual, JL; Puchades, R; Richart, JM; Tormo, A; Torregrosa, M; Uribe, N; Vicent, JM; Viciano, V, 2004) |
| "68 patients with clinical T3-4NxM0 rectal cancer were treated with surgery alone [Group II]." | ( Fukasawa, M; Ishikawa, K; Makuuchi, H; Murayama, C; Ohizumi, Y; Sadahiro, S; Saguchi, T; Suzuki, T; Yasuda, S, 2004) |
| "For patients with resectable rectal cancer receiving concurrent, full dose radiotherapy, the recommended dose of capecitabine for further study is 1800 mg m(-2) day(-1) when given in this schedule." | ( Leong, T; Lim Joon, D; Mackay, J; McKendrick, J; Michael, M; Ngan, SY; Zalcberg, JR, 2004) |
| "Fifty-six rectal cancer patients of postoperative local recurrence were treated with 3-dimensional conformal radiotherapy (66 approximately 68 Gy in 2 Gy daily fraction) combined with chemotherapy (5-Fu 0." | ( Chen, LH; Wu, DH, 2004) |
| "Stage 0 rectal cancer disease is associated with excellent long-term results irrespective of treatment strategy." | ( Campos, FG; Gama-Rodrigues, J; Habr-Gama, A; Kiss, DR; Nadalin, W; Perez, RO; Ribeiro, U; Sabbaga, J; Silva e Sousa, AH, 2004) |
| "The accurate identification of rectal cancer patients with major pathological response after preoperative CRT further supports the necessity of designing prospective studies with new and more accurate was imaging technologies with the main object of offering conservative treatment in responder patients." | ( Capirci, C; Carpi, A; Chierichetti, F; Crepaldi, G; Mandoliti, G; Nicolini, A; Polico, C; Rubello, D, 2004) |
| "Expression of p27 in the residual rectal cancer may therefore identify patients with disease likely to be refractory to standard therapy and for whom investigational approaches should be strongly considered." | ( Guillem, JG; Klimstra, DS; Mazumdar, M; Minsky, BD; Moore, HG; Ruo, L; Saltz, L; Schwartz, GK; Shia, J, 2004) |
| "Recent surgical concepts for primary rectal cancer include the combination of surgery and short-term neoadjuvant radiotherapy (STNR)." | ( Autschbach, F; Gassler, N; Herr, I; Kartenbeck, J; Keith, M; Otto, HF; Schmitz-Winnenthal, H; Ulrich, A; Z'graggen, K, 2004) |
| "30 colorectal cancer patients were enrolled into the study to receive adjuvant chemotherapy 2 weeks after cured resection." | ( Chen, G; Li, S; Liao, H; Pan, ZZ; Wan, DS; Wang, GQ; Zhou, ZW, 2004) |
| "30 colorectal cancer patients have received adjuvant chemotherapy." | ( Chen, G; Li, S; Liao, H; Pan, ZZ; Wan, DS; Wang, GQ; Zhou, ZW, 2004) |
| "In contrast, locally advanced rectal cancers in cUICC-II/-III stages (T3/T4 or N(+)) should receive long-term, 5-FU-based, neoadjuvant chemoradiotherapy according to the excellent results of the CAO/AIO/ARO-94 trial of the German Rectal Cancer Study Group." | ( Becker, H; Ghadimi, BM; Langer, C; Liersch, T, 2005) |
| "In the surgical treatment of advanced rectal cancer, wide lymphadenectomy has been replaced by autonomic nerve preservation because of serious problems such as postoperative urinary and sexual dysfunction." | ( Funahashi, K; Koike, J; Miki, T; Ryu, M; Shimada, M; Teramoto, T, 2005) |
| "Patients with rectal cancer treated by preoperative chemoradiation showed a surprisingly low rate of micrometastasis detection (7%), even in high-risk patients (T3 and T4 tumors)." | ( Coelho Siqueira, SA; Gama-Rodrigues, JJ; Habr-Gama, A; Kiss, DR; Nishida Arazawa, ST; Perez, RO; Rawet, V, 2005) |
| "A total of 23 patients with T3/4 rectal cancer underwent a preoperative radiochemotherapy combined with regional hyperthermia." | ( Amthauer, H; Denecke, T; Felix, R; Gutberlet, M; Hildebrandt, B; Hoffmann, KT; Hünerbein, M; Rau, B; Ruf, J; Wust, P, 2005) |
| "The adjuvant treatment of rectal cancer is a rapidly evolving field." | ( Chao, M; Cullinan, M; Faragher, I; Gibbs, P; Jones, I; McLaughlin, S; Skinner, I; Tjandra, J, 2005) |
| "Eleven patients with rectal cancer who were undergoing preoperative radiation therapy (RT) were studied." | ( Burger, C; Ciernik, IF; Davis, JB; Huser, M; Szekely, G, 2005) |
| "Nineteen consecutive patients with rectal cancer, consisting of seven rectosigmoid, six upper rectal, and six lower rectal cancers, were treated with anterior resection, including seven high, six low, three super-low, and three partial intersphincteric resections, through a suprapubic longitudinal one hand-size incision." | ( Emi, M; Kawabuchi, Y; Minami, K; Toge, T; Yamaguchi, Y, 2005) |
| "We tested the hypothesis that rectal tumors are most responsive to neoadjuvant therapy if they possess p53 and/or caspase 8 activity." | ( Coppola, D; Kelley, ST; Marcet, J; Yeatman, T, 2005) |
| "Patients with a locally advanced rectal cancer, treated by pre-operative CRT were studied." | ( Arriola, E; Biondo, S; Cambray, M; Del Rio, C; Marti-Rague, J; Navarro, M; Novell, V; Pares, D, 2005) |
| "In locally advanced rectal cancer, neoadjuvant 5-fluorouracil (5-FU)-based long-term chemoradiotherapy leads to marked tumor reduction and decrease of local recurrence rate." | ( Aust, DE; Baretton, GB; Becker, H; Häusler, P; Jakob, C; Liersch, T; Meyer, W; Schwabe, W, 2005) |
| "A 59-year-old male patient with rectal cancer 2 cm in diameter (T2) at the peritoneal reflection with suspicious left lateral node metastasis was treated with 400 mg of preoperative oral uracil and tegaful (UFT) for 5 weeks, 5 days a week in combination with concomitant radiotherapy of 45 Gy per 25 fractions for 5 weeks." | ( Arihiro, K; Emi, M; Hironaka, K; Kawabuchi, Y; Ohshita, A; Sakatani, A; Yamaguchi, Y, 2005) |
| "Forty patients with rectal cancer (T3-T4 and/or N+) received radiotherapy (1." | ( Aydin, S; Baurain, JF; Canon, JL; Coche, JC; Coster, B; Duck, L; Gilbeau, L; Honhon, B; Humblet, Y; Kartheuser, A; Kerger, J; Kirkove, C; Laurent, S; Machiels, JP; Octave-Prignot, M; Remouchamps, V; Scalliet, P; Sempoux, C; Van Maele, P, 2005) |
| "For patients with rectal cancer treated with full thickness local excision the risk of mesorectal nodal metastases has to be very low." | ( Bujko, K; Kepka, L; Nasierowska-Guttmejer, A; Nowacki, MP; Oledzki, J; Rogowska, D; Serkies, K; Stryczyńska, G; Suwiński, R; Tokar, P; Wieczorek, A; Winkler-Spytkowska, B, 2005) |
| "Patients with clinically unresectable rectal cancer or for whom resection with histologically clear (R0) surgical margins was unlikely received continuous capecitabine (500-825 mg/m2 twice daily, 7 days/week), oxaliplatin 2-h intravenous infusion (130 mg/m2 days 1 and 29) and pelvic radiotherapy (Monday-Friday for 5 weeks, total dose 45 Gy in 25 daily 1." | ( Falk, SJ; Glynne-Jones, R; Maughan, TS; McDonald, AC; Sebag-Montefiore, D, 2006) |
| "Patients who had rectal cancer with a distal margin within 6 cm of the anal verge had the anus included in the field of radiotherapy (Group A, n = 26)." | ( Chao, MW; Gibbs, P; Hiscock, R; Lim, JF; Tjandra, JJ, 2006) |
| "Twenty pretreatment biopsy samples from rectal cancer patients and their paired, post-CRT surgical specimens (n = 17) were analyzed." | ( El-Hajjar, D; Geradts, J; Groth, J; Iyer, R; Javle, M; Lawrence, D; Watwe, V, 2005) |
| "In 31 patients with a rectal cancer, tumor biopsies were performed before and after pre-operative venous administration of 4 mg/m2, 6 mg/m2, or 10 mg/m2 of MMC." | ( Fukumitsu, T; Ishibashi, N; Matono, K; Mizobe, T; Ogata, Y; Sasatomi, T; Shirouzu, K; Torigoe, S; Yamashita, N; Yanagawa, T, 2006) |
| "One hundred fifteen patients with rectal cancer were treated with oral 5-fluorouracil or Tegafur with preoperative radiotherapy, surgery, and intraoperative electron beam radiation therapy to identify potential pre- and on-treatment characteristics that might be of prognostic value for disease outcome." | ( Alvarez, E; Calvo, FA; Cortés, J; Del Valle, E; Díaz-González, JA; García-Sabrido, JL; Gómez-Espí, M; Muñoz-Jiménez, F, 2006) |
| "Patients with clinical T3/T4 distal rectal cancers were randomly assigned in a phase II study to receive combined neoadjuvant chemoradiotherapy followed by surgical resection." | ( Hanna, N; Hayostek, C; Mitchell, E; Mohiuddin, M; Nichols, C; Shane, R; Willett, C; Winter, K; Yuen, A, 2006) |
| "To describe oncocytic change in rectal cancers that have been treated with chemoradiation before surgery." | ( Chetty, R; Rouzbahman, M; Serra, S, 2006) |
| "Approximately 1 out of 10 advanced rectal cancers after preoperative radiotherapy or radiochemotherapy was characterized by DIS of over 5 mm." | ( Bujko, K; Chmielik, E; Huzarski, T; Karmolinski, A; Kepka, L; Majewski, P; Nasierowska-Guttmejer, A; Nowacki, MP; Sopylo, R; Sygut, J; Wandzel, P; Wojnar, A, 2006) |
| "Stage II-III rectal cancer patients received 2 cycles of bolus 5-FU (425 mg/m2) and leucovorin (LV) (20 mg/m2) on days 1-5 q3w followed by oral capecitabine (800 mg/m2 bid) continuously during pelvic radiotherapy (total 50." | ( Bajetta, E; Beretta, E; Buzzoni, R; Di Bartolomeo, M; Dognini, G; Ferrario, E; Mancin, M; Mariani, L; Valvo, F, 2006) |
| "Accepted management for colorectal cancer (CRC) involves resection of the primary neoplasm and chemotherapy; the debate continues over the most beneficial order of these components." | ( Chaudhury, P; Hayashi, S; Horton, PJ; Jass, JR; Marcus, VA; Martinie, JB; Metrakos, P; Znajda, TL, 2006) |
| "Local recurrence of rectal cancer remains a significant clinical problem despite multi-modality therapy." | ( Busch, TM; Davis, GJ; Del Piero, F; Hahn, SM; Kapatkin, AS; Reineke, E; Ross, HM; Smelstoys, JA; Wang, H; Yodh, AG; Zhu, TC, 2006) |
| "The files of 89 patients with rectal cancer, 43 treated preoperatively with oral capecitabine and 46 with intravenous 5-FU, were reviewed, and the outcome of the groups was compared." | ( Brenner, B; Dreznik, Z; Dror, Y; Fenig, E; Figer, A; Idelevich, E; Loven, D; Nudelman, I; Shani, A; Stemmer, SM; Sulkes, A; Yerushalmi, R, 2006) |
| "A sample of 83 rectal cancer patients in Dukes' stages B2 or C who started a chemoradiotherapy treatment followed by surgery, have filled in the EORTC core questionnaire QLQC30 and the colorectal module QLQ-CR38, in three moments during the treatment and follow-up periods: at the beginning of the treatment, at the end of the chemoradiotherapy, and after surgery." | ( Arias de la Vega, F; Arraras Urdaniz, JI; Manterola Burgaleta, A; Martínez Aguillo, M; Salgado Pascual, E; Vera García, R; Villafranca Iturre, E, 2006) |
| "In Miles operation of rectal cancer, the chemoembolization of bilateral internal iliac arteries is a safe and effective therapy, and it can improve the efficacy of rectal cancer both in the short and long run." | ( Hao, SH; Liu, FL, 2006) |
| "In patients with locally advanced rectal cancer previously treated with neoadjuvant radiochemotherapy, the combined evaluation of pathologic stage and after-radiochemotherapy (18)F-FDG PET at restaging identified a subgroup of patients characterized by good response to radiochemotherapy and a more favorable prognosis." | ( Boni, G; Capirci, C; Chierichetti, F; Crepaldi, G; Fanti, S; Mandoliti, G; Mariani, G; Polico, C; Rampin, L; Rubello, D; Salviato, S, 2006) |
| "16 patients with locally advanced rectal cancer were treated with preoperative pelvic irradiation (45-50 Gy) sensitized with oral tegafur (400 mg for every 8 hours daily)." | ( Aldaz, A; Alvarado, A; Arranz, JA; Calvo, FA; de la Mata, D; García, R; Giráldez, J; Serrano, J; Zufía, L, 2006) |
| "Some rectal cancers respond well to preoperative neoadjuvant therapy while others are inherently resistant or develop resistance during the treatment." | ( Debucquoy, A; Geboes, K; Goethals, L; Haustermans, K; Mc Bride, WH; Roels, S, 2006) |
| "Histologic tumor regression (TR) in rectal cancer after preoperative chemoradiotherapy (CT/RT) may be useful as a surrogate end point for early treatment efficacy, but little is known about its prognostic value." | ( Aust, DE; Baretton, GB; Becker, H; Häusler, P; Jakob, C; Kulle, B; Liersch, T; Meyer, W; Schwabe, W, 2006) |
| "Patients with rectal cancer are at high risk of disease recurrence despite neoadjuvant radiochemotherapy with 5-Fluorouracil (5FU), a regimen that is now widely applied." | ( Bauer, J; Bouzourene, H; Coucke, P; Leyvraz, S; Matter, M; Stupp, R; Voelter, V; Vuilleumier, H; Zouhair, A, 2006) |
| "In patients with rectal cancer who receive preoperative radiotherapy, adding fluorouracil-based chemotherapy preoperatively or postoperatively has no significant effect on survival." | ( Bardet, E; Beny, A; Bosset, JF; Calais, G; Collette, L; Daban, A; Maingon, P; Mineur, L; Ollier, JC; Radosevic-Jelic, L, 2006) |
| "Preoperative radiochemotherapy for rectal cancer causes a high rate of moderate-to-severe toxicities and is associated with only moderate survival benefits." | ( Hamada, K; Izumi, M; Kashiwabara, K; Kawate, S; Nakamura, S; Ogawa, T; Ohwada, S; Sato, Y, 2006) |
| "Ten patients with locally advanced rectal cancer were included and underwent long-course preoperative chemoradiotherapy (total dose 45 Gy, 1." | ( Becker, K; Geinitz, H; Lordick, F; Rosenberg, R; Rummeny, E; Schwaiger, M; Siewert, JR; Stahl, A; Stollfuss, J; Wieder, HA, 2007) |
| "In preoperative chemoradiotherapy for rectal cancer, the pathologic response could be improved by administering capecitabine 1 hour before radiotherapy." | ( Ahn, SD; Chang, HM; Choi, EK; Choi, WS; Jang, SJ; Kim, HC; Kim, JC; Kim, JH; Kim, TW; Lee, SW; Ryu, MH; Shin, SS; Yu, CS, 2007) |
| "Forty patients with rectal cancer (T3-T4, and/or N+, endorectal ultrasound) received preoperative radiotherapy (1." | ( Aydin, S; Bonny, MA; Canon, JL; Coche, JC; Coster, B; Daisne, JF; Duck, L; Haustermans, K; Honhon, B; Humblet, Y; Kartheuser, A; Kerger, J; Kirkove, C; Laurent, S; Machiels, JP; Peeters, M; Roels, S; Scalliet, P; Sempoux, C; Van Cutsem, E, 2007) |
| "A 52-year-old malnourished man with rectal cancer had been treated with continuous epidural block for the relief of pain in the left thigh." | ( Kasai, K; Osawa, M, 2007) |
| "Among the patients with rectal cancer, 5 had locally advanced disease and were treated with chemoradiation therapy." | ( Fakih, MG; Reddy, N; Yu, J, 2007) |
| "Seventy rectal cancer patients treated by neoadjuvant radiotherapy were included in the study." | ( Assenat, E; Azria, D; Bibeau, F; Cellier, D; Grenier, J; Ho-Pun-Cheung, A; Lopez-Crapez, E; Rouanet, P; Senesse, P; Thezenas, S; Ychou, M, 2007) |
| "Patients with stage II or stage III colorectal cancer (CRC) were randomly assigned to receive preoperative hepatic and regional arterial chemotherapy (PHRAC group, n = 110) or surgery alone (control group, n = 112)." | ( Jianhua, W; Jiemin, C; Li, R; Weixin, N; Xinyu, Q; Xu, J; Yanhan, L; Zhiping, Y; Zhong, Y, 2007) |
| "Ninety-one colorectal cancer patients with liver metastasis were treated by FOLFOX6 regimen." | ( Chen, G; Ding, PR; Fang, YJ; Li, LR; Lu, ZH; Pan, ZZ; Wan, DS; Wang, GQ; Wu, XJ; Zhou, ZW, 2007) |
| "Adequate lymph node assessment in colorectal cancer is crucial for prognosis estimation and further therapy stratification." | ( Anthuber, M; Arnholdt, HM; Kerwel, TG; Märkl, B; Wagner, T, 2007) |
| "Prediction of rectal cancer response to preoperative, neo-adjuvant chemo-radiation therapy (CRT) provides the opportunity to identify patients in whom a major response is expected and who may therefore benefit from alternative surgical approaches." | ( Banti, E; Capirci, C; Crepaldi, G; Erba, PA; Fanti, S; Galeotti, F; Gava, M; Mariani, G; Muzzio, PC; Rampin, L; Rubello, D, 2007) |
| "In locally advanced rectal cancer, preoperative infusional chemotherapy combined with radiation was found to be less toxic than bolus chemotherapy and radiotherapy." | ( Elsaleh, H; Joseph, D; Kaminski, A, 2007) |
| "Patients with rectal cancer undergoing neoadjuvant therapy, definitive surgical resection, and FDG-PET/CT before and 4-6 weeks after neoadjuvant treatment were included." | ( Choti, MA; Gearhart, SL; Jacene, HA; Lavely, WC; Melton, GB; Schulick, RD; Wahl, RL, 2007) |
| "Twenty-one rectal cancer patients over 3 years underwent neoadjuvant treatment, serial FDG-PET/CT, and resection." | ( Choti, MA; Gearhart, SL; Jacene, HA; Lavely, WC; Melton, GB; Schulick, RD; Wahl, RL, 2007) |
| "Patients with colorectal cancer treated from May 6, 2004, to April 25, 2005." | ( Fujita, S; Ikeda, E; Kondo, K; Moriya, Y; Ohue, M; Saito, N; Takii, Y; Yamada, T, 2007) |
| "121 locally advanced middle-low rectal cancer patients were treated with preoperative radiotherapy or chemoradiotherapy followed by surgery after rest of 4 to 6 weeks." | ( Cao, WG; Che, JF; Jin, YN; Li, H; Ma, T; Xi, WQ; Xu, HP; Zhao, R, 2007) |
| "The standard management of rectal cancer continues to be defined by the results of randomized, clinical trials exploring the optimal timing and use of adjuvant chemotherapy and radiation therapy in relation to surgery." | ( Chao, M; Fong, A; Gibbs, P; Jones, IT; Kipp, D; Lim, L; McLaughlin, S; Millar, JL; Rezo, A; Shapiro, J, 2007) |
| "Standard therapy for locally advanced rectal cancer (LARC) is concurrent neo-adjuvant chemo-radiation using infusional 5-fluorouracil (CIV-5-FU)." | ( Almhanna, K; Hashmi, S; Kim, R; Saif, MW; Zelterman, D, 2008) |
| "Twenty-five patients diagnosed with rectal cancer T3-4 N0-1 M0-1 and candidates for preoperative radiotherapy underwent PET/CT simulation after injection of 5." | ( Bassi, MC; Brambilla, M; Cannillo, B; Inglese, E; Krengli, M; La Mattina, P; Loi, G; Sacchetti, G; Turri, L, 2008) |
| "Here, we report a case of metastatic rectal cancer showing a complete response (CR) to cycle 4 in FOLFIRI regimen, while maintaining a CR status for over 11 months and good QOL, as a result of chemotherapy with 4 cycles of FOLFIRI followed by UFT." | ( Baba, K; Matsuda, M; Tashima, R; Yamashita, Y; Yokoyama, S, 2007) |
| "We report a case of advanced rectal cancer successfully treated with a combination of S-1 and CPT-11 as neoadjuvant chemotherapy." | ( Han, I; Hatori, S; Iwasaki, H; Murakami, H; Suzuki, M; Takanashi, Y; Yamakawa, M, 2007) |
| "Treatment of rectal cancer over the last two decades has evolved with changes in techniques of surgery and radiation based on national and international trials." | ( Phang, PT; Pinsk, I, 2007) |
| "The management of rectal cancer has undergone significant evolution with advances in surgery, radiation therapy, and chemotherapy." | ( Bendell, JC; Czito, BG; Willett, CG, 2007) |
| "Patients with locally advanced rectal cancer received radiotherapy and concurrently chemotherapy consisting 5-Fu/capecitabine in a continuous or intermittent application and irinotecan in two different total doses (240 vs." | ( Fietkau, R; Foitzik, T; Klar, E; Klautke, G; Küchenmeister, U; Ludwig, K; Prall, F; Semrau, S, 2007) |
| "We report two cases of advanced low rectal cancer, with preoperative chemo-radiation therapy leading to a complete histological response." | ( Fujita, H; Jida, M; Kubo, M; Maeda, H; Mizuta, M; Shirakawa, K; Sogabe, O; Udaka, T; Waki, N, 2007) |
| "Previously irradiated recurrent rectal cancer is a formidable patient threat with limited treatment options." | ( Begossi, G; Belliveau, J; DiSiena, M; Gustafson, E; Wanebo, HJ, 2008) |
| "Patients with rectal T3-T4 and/or N0-N+ rectal cancer received capecitabine 825 mg/m(2) twice daily Monday through Friday and oxaliplatin 60 mg/m(2) intravenously on Days 1, 8, and 15, concurrently with intensity-modulated radiotherapy." | ( Arbea, L; Aristu, JJ; Azcona, JD; Díaz-González, JA; García-Foncillas, JM; Hernández-Lizoain, JL; Martínez-Monge, R; Moreno, M; Rodriguez, J; Sola, JJ, 2008) |
| "Ki67 has, like TS, predictive value in rectal cancer patients after neoadjuvant 5-FU based chemoradiotherapy." | ( Aust, DE; Baretton, GB; Becker, H; Jakob, C; Liersch, T; Meyer, W, 2008) |
| "Sixty patients with locally advanced rectal cancer were treated with preoperative chemoradiation." | ( de Bruin, AF; de Wilt, JH; Ferenschild, FT; Nuyttens, JJ; Planting, AS; Verhoef, C, 2008) |
| "The standard adjuvant therapy for rectal cancer is 5-fluorouracil (5-FU) often combined with radiotherapy." | ( De Bleecker, JL; Pauwels, WJ; Werbrouck, BF, 2008) |
| "Local therapy for early rectal cancer is a valid alternative to the classical radical operation, which has a higher morbidity and mortality rate." | ( Baldarelli, M; Bartolacci, S; Grillo Ruggeri, F; Guerrieri, M; Lezoche, E; Mantello, G; Organetti, L, 2008) |
| "Tumor biopsies from 35 patients with rectal cancer before therapy and parallel tumor biopsies from 31 patients two weeks after starting preoperative capecitabine chemoradiotherapy were taken." | ( Dvorak, J; Izakovicova Holla, L; Kocakova, I; Sefr, R; Svoboda, M; Tichy, B; Vrtkova, I, 2008) |
| "Locally advanced rectal cancer is frequently treated with neoadjuvant chemoradiotherapy to reduce local recurrence and possibly improve survival." | ( Armstrong, J; Beddy, D; Fennelly, D; Gibbons, D; Hyland, JM; Lim, C; Moriarty, M; Sheahan, K; White, A; Winter, DC, 2008) |
| "A 75-year-old patient with colorectal cancer was treated by FOLFOX4 therapy." | ( Iwagami, E; Niimi, M; Ono, Y; Tanaka, E; Uto, N; Yamato, M; Yatsuda, C, 2008) |
| "In total, 106 patients with cT3,4 rectal cancer who received preoperative radiotherapy alone or concurrently with capecitabine chemotherapy at Nottingham City Hospital, UK were studied." | ( Bessell, EM; Dhadda, AS; Zaitoun, AM, 2009) |
| "He was diagnosed with lower rectal cancer by colonoscopy and referred to our hospital for therapy." | ( Akagi, K; Fujita, J; Hata, T; Hayashi, S; Ikeda, K; Kagawa, Y; Kato, H; Kawanishi, K; Kitada, M; Maeda, S; Nomura, M; Oshima, N; Sasaki, T; Shimano, T; Shimizu, J; Takamoto, K; Tsukahara, Y, 2008) |
| "We report a CR case of advanced rectal cancer successfully treated with 39 courses of mFOLFOX6." | ( Fujiwara, M; Imai, N; Isaka, T; Kaneko, M; Kobayashi, K; Naota, H; Ogura, S; Otsubo, M; Taniguchi, K, 2009) |
| "CAP-OX-RT as preoperative treatment for rectal cancer induces a remarkable rate of complete or near-complete pathologically documented response and is well tolerated." | ( Bucci, L; Cannella, L; Carlomagno, C; D'Armiento, FP; D'Armiento, MR; De Placido, S; De Stefano, A; Farella, A; Pacelli, R; Pepe, S; Pesce, G; Solla, R, 2009) |
| "The successful management of rectal cancer requires a multidisciplinary approach, with treatment decisions based on precise patient evaluations by a group of clinicians, including surgeons, gastroenterologists, medical and radiation oncologists, radiologists, and pathologists." | ( Hoffe, SE; Meredith, KL; Shibata, D, 2009) |
| "However, the German Rectal Cancer Study Group recently demonstrated that preoperative radiochemotherapy (RCT) was better than postoperative radiochemotherapy in terms of local control." | ( Budach, V; Burock, S; Dietel, M; Koswig, S; Kretzschmar, A; Loy, V; Schlag, PM; Siegel, R; Wernecke, KD, 2009) |
| "Up to 6% of women with colorectal cancer are diagnosed in the reproductive age and are at risk for premature ovarian failure and infertility due to pelvic irradiation and chemotherapy." | ( Elizur, SE; Huang, JY; Levin, D; Meterissian, S; Tan, SL; Tulandi, T, 2009) |
| "Fifty-four patients with T3/T4/N+ rectal cancers were treated on a Phase II trial using preoperative capecitabine and concomitant boost radiotherapy." | ( Cleeland, CS; Crane, CH; Das, P; Delclos, ME; Hundal, M; Janjan, NA; Krishnan, S; Lin, EH; Mendoza, TR; Park, HC; Vadhan-Raj, S; Wang, XS; Zhang, Y, 2009) |
| "In locally advanced rectal cancer, neoadjuvant radiochemotherapy is indicated." | ( Christiansen, H; Ghadimi, M; Hermann, RM; Hess, CF; Liersch, T; Rothe, H; Vorwerk, H, 2009) |
| "Forty-one patients with rectal cancer (T3-4 and/or N+) received preoperative radiotherapy (1." | ( Aydin, S; Daemen, A; De Moor, B; Debucquoy, A; Gevaert, O; Haustermans, K; Libbrecht, L; Machiels, JP; McBride, WH; Penninckx, F; Scalliet, P; Sempoux, C; Stroh, C; Tejpar, S; Vlassak, S, 2009) |
| "In patients with locally advanced rectal cancer (LARC) staging and, after preoperative chemo-radiation therapy (CRT), restaging workup could be useful to tailor therapeutic approaches." | ( Banti, E; Bianchini, E; Capirci, C; Crepaldi, G; Del Favero, G; Facci, E; Galeotti, F; Gava, M; Marano, G; Panzavolta, R; Pasini, F; Rampin, L; Rubello, D, 2009) |
| "The basic principle in the treatment of rectal cancer is the complete surgical removal of the tumor together with the lymphatic drainage region, i." | ( Hempen, HG; Raab, HR; Troja, A, 2009) |
| "Patients with rectal cancer (cT3/4Nx or Tx/N+) received neoadjuvant chemoradiotherapy within clinical studies with irinotecan and capecitabine." | ( Erben, P; Hochhaus, A; Hofheinz, RD; Horisberger, K; Kaehler, G; Muessle, B; Post, S; Stroebel, P; Wenz, F; Willeke, F; Woernle, C, 2009) |
| "Treatment of rectal cancer requires a multidisciplinary approach with standardized surgical, pathological and radiotherapeutic procedures." | ( Elsayed, MI; Elwanis, MA; Maximous, DW; Mikhail, NN, 2009) |
| "A total number of 53 metastatic colorectal cancer patients were treated with BEV-CAPIRI regimen." | ( Bozkurt, MT; Cirak, Y; Degirmenci, M; Demir Piskin, G; Durusoy, R; Gorumlu, G; Karabulut, B; Karaca, B; Sanli, UA; Tunali, D; Uslu, R, 2010) |
| "Following preoperative treatment of rectal cancer with chemoradiotherapy (CRT), a complete pathological response (CPR) can be seen in the surgical specimen." | ( Ciccocioppo, A; Hewett, PJ; Rieger, NA; Stephens, JH, 2009) |
| "A postoperative rectum cancer patient with lung metastasis undergoing hemodialysis was treated with mFOLFOX6 therapy." | ( Fujita, M; Kataoka, Y; Katayama, T; Koide, T; Matsuda, H; Okuda, M; Yamagishi, Y, 2009) |
| "Forty patients with rectal cancer underwent 5-fluorouracil based chemoradiotherapy followed by curative surgery." | ( Inoue, Y; Kusunoki, M; Miki, C; Saigusa, S; Tanaka, K; Toiyama, Y; Yokoe, T, 2009) |
| "Patients with locally advanced rectal cancer undergoing preoperative radiotherapy have disparity in pathological tumor regression." | ( Ding, PR; Lin, JZ; Pan, ZZ; Wan, DS; Zeng, ZF, 2009) |
| "Data concerning the type and stage of rectal cancer, multimodal treatment (surgery with or without neoadjuvant therapy or adjuvant therapy) and treatment according to the level of medical care of hospitals were recorded from 2000 to 2008." | ( Dommisch, K; Sauer, J; Sobolewski, K, 2009) |
| "Preoperative treatment of rectal cancer with combined chemotherapy and radiation therapy has become a widely accepted strategy." | ( Chang, M; George, TJ; Grobmyer, S; Hochwald, S; King, J; Larson, B; Marsh, Rde W; Mendenhall, WM; Siddiqui, T; Zlotecki, RA, 2010) |
| "We report a case of recurrent rectal cancer with multiple lung metastases successfully treated with S-1 and CPT-11 combination chemotherapy." | ( Hara, Y; Kawano, T; Maekawa, K; Minami, Y; Ueda, S, 2009) |
| "In advanced rectal cancer with distant metastases, chemoradiation therapy for local control plus systemic chemotherapy could be an alternative to improve quality of life." | ( Imanishi, T; Iwatani, Y; Kamigaki, T; Kuroda, D; Kuroda, Y; Matsuda, Y; Nakamura, T; Sakai, T; Sumi, Y; Suzuki, S; Takase, S; Yamashita, K, 2009) |
| "We describe a case of locally recurrent rectal cancer that was successfully treated with radiation and chemotherapy with S-1; this treatment resulted in long-term survival of the patient with a good performance status." | ( Baba, H; Fujiwara, N; Goseki, N; Kuwabara, H; Nakajima, K; Nakamura, H; Tamai, S, 2009) |
| "A 63-year-old female diagnosed as rectal cancer underwent low anterior resection and received adjuvant chemotherapy (folinate/tegafur/uracil therapy)." | ( Endo, W; Fujie, Y; Fukunaga, H; Hojou, S; Kakutani, A; Maeura, Y; Ogino, T; Ota, H; Shimizu, K; Toyoda, Y; Yoshioka, A; Yoshioka, S, 2009) |
| "Twenty-three rectal cancer patients were included, which underwent perfusion-CT imaging before (pre-scan) and after treatment (post-scan)." | ( Aerts, HJ; Backes, WH; Buijsen, J; Janssen, MH; Kierkels, RG; Lambin, P; Lammering, G; Ollers, MC, 2010) |
| "Hypofractionated radiotherapy of rectal cancer leads to an increased tumor perfusion as reflected by an elevated K(trans), possibly improving the bioavailability of cytotoxic agents in rectal tumors, often administered early after radiotherapy treatment." | ( Aerts, HJ; Backes, WH; Buijsen, J; Janssen, MH; Kierkels, RG; Lambin, P; Lammering, G; Ollers, MC, 2010) |
| "Patients with poor-risk rectal cancer defined by MRI can be at high risk of disease recurrence despite standard chemoradiotherapy and optimum surgery." | ( Barbachano, Y; Brown, G; Chau, I; Chua, YJ; Cunningham, D; Massey, A; Oates, JR; Tait, D; Tebbutt, NC; Wotherspoon, A, 2010) |
| "Radiochemotherapy of rectal cancer leads to significant early changes in the metabolic activity of the tumor, which was not the case early after hypofractionated radiotherapy alone, despite the higher radiotherapy dose given." | ( Buijsen, J; de Ruysscher, D; Janssen, MH; Lambin, P; Lammering, G; Ollers, MC; van den Bogaard, J; van Stiphout, RG, 2010) |
| "Analysing VEGF expression levels in rectal cancer may be of benefit in estimating the effects of neoadjuvant chemoradiotherapy and in predicting systemic recurrence after rectal cancer surgery." | ( Inoue, Y; Kusunoki, M; Miki, C; Okugawa, Y; Saigusa, S; Tanaka, K; Toiyama, Y; Yokoe, T, 2010) |
| "In colorectal cancer, increased response rates are achieved by cetuximab and panitumumab within standard chemotherapy schedules, but not in chemoradiation regimens." | ( Glynne-Jones, R; Harrison, M; Mawdsley, S, 2010) |
| "A total of 238 rectal cancer patients treated in a neo-adjuvant setting by a fluoropyrimidines-based chemo-radiotherapy (RT) were genotyped for 25 genetic polymorphisms in 16 genes relevant for treatment-associated pathways." | ( Agostini, M; Biason, P; Canzonieri, V; Cecchin, E; De Mattia, E; De Paoli, A; Friso, ML; Nitti, D; Pucciarelli, S; Sigon, R; Toffoli, G; Visentin, M, 2011) |
| "Standard therapy for stage II/III rectal cancer consists of a fluoropyrimidine and radiation therapy followed by surgery." | ( Bernard, SA; Calvo, BF; Caskey, LS; Chakravarthy, AB; Chan, E; Goldberg, RM; Ivanova, A; Kim, HJ; Myers, MO; O'Neil, BH; Raftery, L; Sanoff, HK; Tepper, JE; Wise, PE, 2010) |
| "Sixty-four consecutive rectal cancer patients with stage I-III disease treated between November 2004 and June 2008 were analyzed prospectively." | ( Baek, JH; Garcia-Aguilar, J; McKenzie, S; Pigazzi, A, 2010) |
| "Pathologic complete remission (CR) of rectal cancer after neoadjuvant chemoradiation therapy (CRT) is generally confirmed by routine hematoxylin and eosin (H&E) staining." | ( Cho, YB; Chun, HK; Kim, HC; Kim, SH; Lee, WY; Shin, HJ; Yun, HR; Yun, SH, 2010) |
| "Twenty-two rectal cancer patients treated with long course CRT were included." | ( de Keyzer, F; Deroose, C; Haustermans, K; Lambrecht, M; Penninckx, F; Roels, S; Sagaert, X; van Cutsem, E; Vandecaveye, V, 2010) |
| "In patients with advanced rectal cancer, preoperative chemoradiotherapy is superior to postoperative chemoradiotherapy because of causing less toxicity and achieving higher rates of sphincter preservation and curative resection." | ( Hama, T; Horiuchi, T; Ishida, K; Miyagawa, Y; Sakaguchi, S; Shono, Y; Tabuse, K; Tamagawa, K; Tanishima, H; Tsubakihara, H; Tsujimoto, T; Uemura, R, 2010) |
| "We report 2 patients with colorectal cancer who underwent percutaneous coronary intervention (PCI) for unstable angina soon after administration of chemotherapy including BV." | ( Okada, Y; Okura, Y; Takii, Y, 2010) |
| "Tumor response of rectal cancer to preoperative chemoradiotherapy (CRT) varies considerably." | ( Boender, PJ; de Wijn, R; Dueland, S; Flatmark, K; Folkvord, S; Giercksky, KE; Grøholt, KK; Hole, KH; Johansen, M; Nesland, JM; Ree, AH; Ruijtenbeek, R, 2010) |
| "We report two cases of colorectal cancer whose serum iron level demonstrated recurrent elevation after chemotherapy." | ( Furuse, J; Hosokawa, Y; Itabashi, M; Iwamoto, N; Kase, Y; Kitagawa, N; Miyazawa, T; Motoori, S; Saisho, H, 2010) |
| "A 59-years-old woman with metastatic rectal cancer treated with bevacizumab, who developed low back pain after 11 cycles of chemotherapy." | ( Hayashi, H; Nakagawa, K; Okamoto, I, 2012) |
| "Standard adjuvant chemoradiotherapy of rectal cancer still consists of 5-fluorouracil (5-FU) only." | ( Baumann, W; Henne-Bruns, D; Kornmann, M; Kreuser, ED; Kron, M; Link, KH; Staib, L; Wiegel, T, 2010) |
| "Patients with R(0)-resected rectal cancer (UICC stage II and III) were stratified and randomised to a 12-month adjuvant chemoradiotherapy with 5-FU, 5-FU+FA, or 5-FU+IFNα." | ( Baumann, W; Henne-Bruns, D; Kornmann, M; Kreuser, ED; Kron, M; Link, KH; Staib, L; Wiegel, T, 2010) |
| "Forty-four patients with rectal cancer treated with 5-FU-based preoperative CRT were prospectively enrolled in this study." | ( Choi, J; Choi, SH; Hur, H; Kang, J; Keum, KC; Kim, H; Kim, NK; Lee, KY; Lee, MY; Min, BS; Shin, SJ, 2011) |
| "Patients with confirmed diagnosis of rectal cancer (T2-4 or N+) were prospectively studied with (18)F-FDG PET before and after neoadjuvant therapy." | ( Alvarez, E; Cabezón, L; Calvo, FA; Carreras, JL; de la Mata, D; García-Alfonso, P; Gómez-Espí, M; González, C; Soria, A, 2010) |
| "Stage II or III rectal cancer patients were evaluated and treated with RT and 5-FU preoperatively (neoadjuvant treatment, NG) or after surgical resection of the cancer (adjuvant treatment, AG)." | ( Andrade, NR; Forones, NM; Gomes, TS; Neto, RA; Oshima, CT, 2011) |
| "Patients with advanced colorectal cancer and unclear K-ras treated by cetuximab combined with chemotherapy have good ORR and OS, and the regimen is safe with less adverse events for them." | ( Guo, GF; Jiang, WQ; Qiu, HJ; Wang, F; Xia, LP; Xu, RH; Zhang, B; Zhou, FF, 2010) |
| "Patients with nonmetastatic distal rectal cancer treated by neoadjuvant chemoradiation therapy, including 50." | ( Gama-Rodrigues, J; Habr-Gama, A; Kessler, H; Marks, J; Perez, RO; Wynn, G, 2010) |
| "Patients with locally advanced rectal cancer treated with neoadjuvant therapy can safely undergo laparoscopic proctectomy with a low rate of complications." | ( Cone, MM; Diggs, BS; Herzig, DO; Lu, KC; Oommen, SC; Rea, JD, 2011) |
| "Adjuvant chemotherapy in rectal cancer is not well defined." | ( Alfonso, R; Corona, J; Custodio, A; de las Heras, M; Dıaz-Rubio, E; Ortega, L; Puente, J; Rodriguez, L; Sanchez, JC; Sastre, J, 2011) |
| "We report here a case of rectal cancer with synchronous multiple liver metastases successfully treated with a combined chemotherapy of modified FOLFOX6 (mFOLFOX6) and bevacizumab." | ( Andou, S; Kitamura, Y; Tokunou, K; Toshimitsu, H; Tsushimi, K; Yamamoto, T, 2010) |
| "We report a case of local recurrent colorectal cancer that has been treated successfully with low-dose oral chemotherapeutic agent." | ( Fujita, S; Ikeda, N; Kanamura, T; Kojima, Y; Nakagawa, K; Ueno, M, 2010) |
| "Nine patients with biopsy proven rectal cancer underwent CT and (18)F-FLT-PET scanning prior to short-term pre-operative radiotherapy (5×5Gy)." | ( Beukema, JC; Havenga, K; Langendijk, JA; Muijs, CT; Pruim, J; van den Bergh, AC; Widder, J, 2011) |
| "Twenty-six rectal cancer patients underwent both MR and PET-CT imaging followed by short-course radiotherapy (RT 5×5 Gy) and surgery within 3 days after RT." | ( Bakers, FC; Beets, GL; Beets-Tan, RG; Buijsen, J; Engelsman, S; Janssen, MH; Lambin, P; Lammering, G; Nap, M; Öllers, M; van den Bogaard, J, 2011) |
| "In 10-24% of patients with rectal cancer who are treated with neoadjuvant chemoradiation, no residual tumor is found after surgery (ypT0)." | ( Bakers, FC; Barbaro, B; Beets, GL; Beets-Tan, RG; Haustermans, K; Lambrecht, M; Lambregts, DM; Maas, M; Valentini, V; Vandecaveye, V, 2011) |
| "Abdominoperineal resection+D3 of rectal cancer was performed, followed by chemotherapy with UFT for 28 days, and then partial resection of liver." | ( Doi, F; Ishikawa, N; Kohro, T; Kusumoto, C; Kusumoto, M; Matsumoto, T; Toyoda, S, 2011) |
| "Patients with T3, T4, or N+ rectal cancer received radiotherapy to a total dose of 50." | ( Alexander, HR; Camphausen, K; Citrin, D; Denobile, J; Libutti, SK; Pingpank, JF; Quezado, M; Royal, RE; Seidel, G; Shuttack, Y; Steinberg, SM; Wood, BJ, 2010) |
| "Patients with primary rectal cancer treated by long-course neoadjuvant chemoradiotherapy followed by surgery had FDG PET performed before and 4 weeks after treatment, before surgical resection was performed." | ( Drummond, E; Heriot, AG; Hicks, RJ; Kalff, V; Link, E; Lynch, AC; Michael, M; Ngan, S; Taouk, Y; Yeung, JM, 2011) |
| "37 patients with resectable rectal cancer were recruited and given three 3-week cycles of preoperative Pemetrexed therapy." | ( Carlsson, G; Derwinger, K; Gustavsson, B; Kälebo, P; Kodeda, K; Swartling, T, 2011) |
| "Patients with locally advanced rectal cancer (cUICC stages II/III) are typically treated with preoperative 5-fluorouracil-based (5-FU-based) radiochemotherapy (RCT)." | ( Becker, H; Beissbarth, T; Christiansen, H; Conradi, LC; Hennies, S; Hess, CF; Liersch, T; Rave-Fränk, M; Schirmer, M; Sprenger, T; Wolff, HA, 2011) |
| "A 50-year-old man with advanced rectal cancer and multiple liver metastases experienced DIC during third-line treatment with cetuximab plus irinotecan, following 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX) plus bevacizumab and 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab." | ( Kondo, C; Mizota, A; Muro, K; Nomura, M; Shitara, K; Takahari, D; Ura, T; Yokota, T, 2011) |
| "We report a case of a Stage IV rectal cancer patient for whom EPA oral nutritional supplements promoted treatment compliance with cancer chemotherapy by resolving a refractory cachectic condition." | ( Hamamura, K; Miki, C; Miyazaki, M; Nakagawa, M; Nakaya, M, 2011) |
| "The management of rectal cancer has undergone significant evolution with advances in surgery, radiation therapy, and chemotherapy." | ( Czito, BG; Willett, CG, 2011) |
| "Patients with locally advanced or low rectal cancer were treated with capecitabine 825 mg/m(2) twice daily on days 1-14 and 22-35, oxaliplatin 50mg/m(2) on days 1, 8, 22 and 29, bevacizumab 5mg/kg on days 14, 1, 15 and 29, and radiation 50." | ( Berry, S; Easaw, J; Hay, J; Kennecke, H; Post, J; Rao, S; Tankel, K; Wong, R; Zhou, C, 2012) |
| "Ninety-six patients with rectal cancer received neoadjuvant therapy (41 were treated with radiotherapy and 55 with chemoradiotherapy) before surgery." | ( Lin, GL; Qiu, HZ; Wu, B; Xiao, Y, 2011) |
| "Results of this small pilot study in rectal cancer patients receiving preoperative radiochemotherapy, showed that ingestion of larger quantities of glutamine given more often as previously reported did not diminish the incidence and severity of diarrhoea and did not affect inflammatory and metabolic activity compared to the placebo treatment with maltodextrin." | ( Anderluh, F; Kompan, L; Mlakar Mastnak, D; Možina, B; Oblak, I; Rotovnik Kozjek, N; Soeters, P; Velenik, V; Zadnik, V, 2011) |
| "Clinically staged T2N0 rectal cancer patients were treated with capecitabine and oxaliplatin during radiation followed by LE." | ( Cataldo, P; Chan, E; Garcia-Aguilar, J; Marcet, J; Medich, D; Oommen, S; Pigazzi, A; Posner, MC; Shi, Q; Thomas, CR, 2012) |
| "Keywords for the search were: "rectal cancer", "preoperative radiotherapy", "phase II-III", "preoperative chemotherapy", "adjuvant chemotherapy" and "surgery"." | ( Bosset, JF; Créhange, G; Maingon, P, 2011) |
| "The finding that some rectal cancers respond to neoadjuvant chemoradiation is broadening new surgical options for the treatment of some of these tumors that, until now, required a total mesorectal excision." | ( Arbea, L; Aristu, J; Baixauli, J; Beorlegui, C; Hernandez-Lizoain, JL; Pastor, C; Sola, J; Subtil, JC, 2011) |
| "Seven patients with rectal cancers which were difficult to ensure surgical margins for because of huge tumors(over 60mm in diameter), invasion to other organs, or severe nodal metastases, were treated with preoperative chemotherapy consisting of 2-10 courses of mFOLFOX6." | ( Fuyuhiro, Y; Hirakawa, K; Inoue, T; Kashiwagi, S; Maeda, K; Nagahara, H; Nakamoto, K; Noda, E, 2011) |
| "For patients with locally advanced rectal cancer (LARC) neoadjuvant chemoradiotherapy is recommended as standard therapy." | ( Bohn, B; Erben, P; Gencer, D; Hofheinz, RD; Hofmann, WK; Horisberger, K; Kähler, G; Kienle, P; Post, S; Schwaab, J; Ströbel, P; Wenz, F, 2011) |
| "54 postoperative colorectal cancer patients received the combination therapy of oxaliplatin and S-1 regimen, repeated every 3 weeks, and evaluate the efficacy after 3 cycles." | ( Jin, ZM; Zhu, QC, 2011) |
| "He was diagnosed as advanced rectal cancer with an invasion of prostate, and we conducted neoadjuvant capecitabine, oxaliplatin, bevacizumab and radiation therapy." | ( Arima, N; Shigaki, N; Sugita, H; Suzuki, S; Yamashita, H; Yokoyama, S, 2011) |
| "BACKGROUND Survival in rectal cancer remains unchanged despite improved treatment modalities." | ( Beynon, J; Hughes, R; Jenkins, G; Parry, J, 2011) |
| "Neoadjuvant chemoradiotherapy for rectal cancer can result in complete disappearance of tumor and involved nodes." | ( Beets, GL; Beets-Tan, RG; Buijsen, J; Engelen, SM; Hulsewé, KW; Jansen, RL; Lambregts, DM; Lammering, G; Leijtens, JW; Maas, M; Nelemans, PJ; Sosef, M; van Dam, RM, 2011) |
| "A total of 41 patients of low rectal cancer were treated with CPT-11, 5-FU therapy or CPT-11 plus 5-FU combined short-term radiotherapy from April 2002 to April 2009." | ( Chen, MX; Fan, L; Hu, XZ; Jiang, HY; Li, CY; Liang, XB; Ma, JJ; Yan, D, 2011) |
| "A total of 38 T3-4/N+ rectal cancer patients received capecitabine-oxaliplatin and radiotherapy followed by surgery." | ( Carlomagno, C; D'Incalci, M; De Placido, S; De Stefano, A; Della Vittoria Scarpati, G; Falcetta, F; Marchini, S; Pepe, S; Singh, VK; Ubezio, P, 2012) |
| "We report a long-term survival case of rectal cancer that was initially thought unresectable treated with chemoradiotherapy (CRT)." | ( Kamiya, A; Kawachi, Y; Maruyama, H; Nagano, H; Nakajima, Y; Ohtsukasa, S; Okazaki, S; Takamatsu, S, 2011) |
| "Forty two patients diagnosed with rectal cancer underwent an FDG-PET-CT for radiotherapy planning." | ( Beets, G; Beets-Tan, R; Buijsen, J; Engelsman, S; Janssen, M; Lambin, P; Lammering, G; van den Bogaard, J; van der Weide, H; van Stiphout, R, 2012) |
| "After nCRT for rectal cancer, postsurgery CEA level may have more prognostic value than pretreatment level." | ( Chang, DT; Hong, JC; Koong, AC; Liauw, SL; McDonnell, SE; Minsky, BD; Song, S, 2012) |
| "In spite of advances in rectal cancer surgery and the use of preoperative 5-fluorouracil-(5-FU) based chemoradiotherapy (CRT) in stage II and III disease distant metastases still occur in about 35-40% of the patients." | ( Brade, J; Gencer, D; Hofheinz, RD; Hofmann, WK; Horisberger, K; Kienle, P; Kripp, M; Post, S; Welzel, G; Wenz, F; Wieneke, J, 2012) |
| "Assessment of rectal cancer response to neoadjuvant chemoradiotherapy by FDG-PET provides no prognostic information." | ( Akhurst, TJ; Guillem, JG; Larson, SM; Leibold, T; Mazumdar, M; Riedel, ER; Ruby, JA; Saltz, LB; Shia, J, 2012) |
| "Treatment standard for patients with rectal cancer depends on the initial staging and includes surgical resection, radiotherapy as well as chemotherapy." | ( Büchler, MW; Combs, SE; Debus, J; Dosanjh, M; Engenhart-Cabillic, R; Fossati, P; Habermehl, D; Jäger, D; Jäkel, O; Kieser, M; Orrechia, R; Pötter, R; Weitz, J, 2012) |
| "To diagnose rectal cancer and monitor treatment response after preoperative concurrent chemoradiotherapy (CCRT) in rectal cancer patients using proton-1 magnetic resonance spectroscopy ((1)H-MRS)." | ( Chun, HK; Kim, MJ; Kim, SH; Lee, JH; Lee, SJ; Lim, HK; Yun, SH, 2012) |
| "We enrolled 134 rectal cancer patients before treatment, of whom 34 underwent preoperative CCRT and follow-up MR spectroscopy before surgery." | ( Chun, HK; Kim, MJ; Kim, SH; Lee, JH; Lee, SJ; Lim, HK; Yun, SH, 2012) |
| "To estimate the metabolic activity of rectal cancers at 6 and 12 weeks after completion of chemoradiation therapy (CRT) by 2-[fluorine-18] fluoro-2-deoxy-d-glucose-labeled positron emission tomography/computed tomography ([(18)FDG]PET/CT) imaging and correlate with response to CRT." | ( Buchpiguel, CA; Campos, FG; Gama-Rodrigues, J; Habr-Gama, A; Imperiale, AR; Lynn, PB; Nahas, SC; Ono, CR; Perez, RO; Proscurshim, I; São Julião, GP; Sousa, AH, 2012) |
| "Patients with T3/T4 or node positive rectal cancer were treated with capecitabine 1,000 mg/m(2) twice daily (BID) days 1-14, and irinotecan 200 mg/m(2) on day 1 every 21 days for 2 cycles, followed by capecitabine 825 mg/m(2) BID days 1-5 per week with concurrent radiotherapy 50." | ( Bufill, J; Burns, M; Cardenes, H; Chiorean, EG; Clark, R; Coleman, N; Curie, C; Hinkle, DT; LeBlanc, J; Loehrer, PJ; Robb, B; Sanghani, S; Schiel, MA; Tong, Y; Yu, M, 2012) |
| "A 61-year-old man with rectal cancer, who was treated successfully with surgery and chemotherapy 1 year ago, underwent 18F-FDG PET/CT for restaging, which showed a focal hot spot in the left scapula mimicking osseous metastasis." | ( Bom, HS; Choi, YD; Chong, A; Ha, JM; Lee, JS; Min, JJ; Oh, JR; Song, HC, 2012) |
| "Standard treatment for locally advanced rectal cancer (cT3/4 and/or cN+) includes neoadjuvant chemoradiotherapy with fluoropyrimidines (capecitabine or 5-fluorouracil) followed by radical surgical resection." | ( Fabian, P; Gombosova, J; Kocakova, I; Nekvindova, J; Radova, L; Sana, J; Slaby, O; Svoboda, M; Vyzula, R, 2012) |
| "In locally advanced rectal cancer (LARC) patients, major response to neoadjuvant radiotherapy (NR) has been associated with favorable long-term outcomes." | ( Flejou, JF; Lefèvre, JH; Parc, Y; Svrcek, M; Tiret, E; Tranchart, H, 2013) |
| "Following diagnosis of T4 rectal cancer, preoperative chemotherapy was initiated with the aim of downstaging the tumor and avoiding total pelvic exenteration." | ( Akasaka, H; Hakamada, K; Koyama, M; Morohashi, H; Murata, A; Sakamoto, Y; Yokoyama, H, 2012) |
| "An approximately 50-year-old man with rectal cancer(RbP)[ cT3(cA), cN3, cM0, and cStage IIIb] who desired anus preservation was administered mFOLFOX6 therapy." | ( Ito, Y; Kimura, A; Kubo, N; Kudo, Y; Kurushima, M; Morita, T; Nishikawa, S; Takahashi, K; Tokura, T; Umehara, Y; Yachi, T, 2012) |
| "After curative resection for rectal cancer with uterus invasion, UFT/Leucovorin was administered orally for 16 months." | ( Hirata, K; Mizushima, Y; Okuya, K, 2013) |
| "T3-4 and/or N+ rectal cancer patients were treated prospectively with capecitabine-based chemoradiation and total mesorectal excision 7-8 weeks later." | ( Alessi, A; Avuzzi, B; Bampo, C; Bertarelli, G; Biondani, P; Bombardieri, E; Chiruzzi, C; Crippa, F; de Braud, F; Di Bartolomeo, M; Fantini, S; Mariani, L; Milione, M; Pietrantonio, F; Valvo, F, 2013) |
| "Local antibiotic therapy in rectal cancer surgery lowered the incidence of postoperative fever of unknown origin and permitted shorter hospitalization after surgery." | ( Dziki, A; Kołacińska, A; Morawiec, Z; Pawlak, M, 2012) |
| "Stage II and III rectal cancer patients received, after total mesorectal excision, 2 cycles of XELOX regimen (oxaliplatin 130 mg/m(2) on day 1; capecitabine 1000 mg/m(2) bid on day 1 to 14, q21), followed by capecitabine (800 mg/m(2) bid daily; 20% dose at 12:00 AM and 80% dose at 12:00 PM) administered continuously during pelvic radiation (total 50." | ( Bajetta, E; Biondani, P; Buzzoni, R; Di Bartolomeo, M; Dotti, KF; Ferrario, E; Formisano, B; Gevorgyan, A; Grassi, P; Mariani, L; Pietrantonio, F; Valvo, F, 2014) |
| "Locally advanced fixed T4 rectal cancer has a poor prognosis and no standard treatment strategy." | ( Barsukov, YA; Fedyanin, MY; Gordeyev, SS; Perevoshikov, AG; Tkachev, SI, 2013) |
| "Management of locally advanced rectal cancer is complex because curative treatment routinely involves administration of surgery, chemotherapy, and radiation." | ( Schrag, D, 2013) |
| "We report a case of advanced rectal cancer treated with chemotherapy, for which laparoscopic splenectomy had been effective for thrombocytopenia." | ( Arita, S; Koike, N; Ohshima, Y; Shinozaki, E; Takeuchi, T, 2013) |
| "Eighteen patients with rectal cancer and synchronous liver metastases, who had undergone laparoscopic colorectal resection and simultaneous treatment for liver metastases, were retrospectively reviewed." | ( Chen, F; Chen, K; Ding, XM; Hu, BS; Leng, JJ; Tan, HM; Tan, JW; Zhu, Z, 2013) |
| "Changes in the treatment of rectal cancer during the past decades have led to an increase in sphincter preservation with a consecutive decline in abdominoperineal resection rates." | ( Buchner, S; Dinnewitzer, A; Jäger, T; Nawara, C; Öfner, D; Wolfgang, H, 2013) |
| "Young rectal cancer patients in India tended to present more frequently with locally advanced tumors resulting in a higher proportion being treated with NACT-RT." | ( Barreto, SG; Chaubal, GN; DeSouza, A; Gaikwad, V; Goel, M; Shrikhande, SV; Suradkar, K; Talole, S, 2014) |
| "Locally advanced rectal cancer is commonly treated with chemoradiation prior to total mesorectal excision (TME)." | ( Chang, GJ; Crane, CH; Das, P; Delclos, ME; Eng, C; Garrett, CR; Kelly, P; Krishnan, S; Rodriguez-Bigas, MA; Sandulache, VC; Skibber, JM; Skinner, HD, 2013) |
| "The treatment of rectal cancer has evolved significantly in recent decades." | ( Büchler, MW; Kulu, Y; Ulrich, A, 2013) |
| "Treatment of locally advanced rectal cancer (LARC) includes preoperative radiation therapy with or without chemotherapy followed by radical surgery, but the clinical outcome is uncertain." | ( Crott, R; D'Hondt, L; de Cannière, L; Krug, B; Vander Borght, T, 2013) |
| "Patients with clinical stage II or III rectal cancer were treated with radiotherapy of 44 Gy in 22 fractions." | ( Chen, HC; Chen, HH; Chen, WT; Chien, CR; Hsiao, CF; Lee, HH; Lin, TC; Lin, TY; Liu, TW; Wang, LW, 2014) |
| "In cases of advanced rectal cancer, preoperative chemoradiotherapy( CRT) serves to improve the local control rate, survival rate, radical resection rate, and/or probability of sphincter muscle preservation." | ( Amagasa, H; Ami, K; Ando, M; Arai, K; Fujiya, K; Fukuda, A; Ganno, H; Gokita, K; Imai, K; Kamikozuru, H; Kawai, Y; Nagahama, T; Okada, Y; Seki, R; Takasaki, J; Takeuchi, S; Tei, S, 2013) |
| "We encountered a case of colorectal cancer with pelvic abscess treated with radical surgery following colostomy and chemotherapy." | ( Goseki, N; Kuwabara, H; Liu, B; Mitsuoka, A; Nakajima, K; Sanada, T; Watanabe, S, 2013) |
| "The presented patient with stage IV rectal cancer and liver metastases was in a unique situation linked to its inclusion in a reversed treatment and the use of neoadjuvant chemotherapy alone." | ( Gervaz, P; Mentha, G; Morel, P; Naiken, SP; Roth, A; Rubbia-Brandt, L; Thomopoulos, T; Toso, C, 2014) |
| "110 upper rectal cancer patients with locally advanced (pT3-4N0 or pTanyN+) tumors treated with tumor-specific mesorectal excision and no adjuvant radiotherapy were identified from an institutional database at a large academic medical center in Korea." | ( Baik, SH; Chang, JS; Huh, H; Kim, NK; Koom, WS; Lee, Y; Lim, JS; Min, BS, 2014) |
| "Patients with cT2-4N0-2M0 distal rectal cancer treated with CRT (50." | ( Gama-Rodrigues, J; Habr-Gama, A; Lynn, PB; Perez, RO; Proscurshim, I; Sabbagh, C; São Julião, GP, 2014) |
| "Patients with T4 or lymph node-positive rectal cancer were treated with three cycles of XELOX plus bevacizumab and one additional cycle of XELOX." | ( Doki, Y; Fujie, Y; Fujii, M; Hasegawa, J; Ikeda, M; Kato, T; Kim, HM; Miwa, H; Miyake, Y; Mizushima, T; Mori, M; Nezu, R; Nishimura, J; Noura, S; Sekimoto, M; Takemasa, I; Takemoto, H; Tamagawa, H; Yamamoto, H, 2014) |
| "Twenty-seven patients with rectal cancer underwent (18)F-FDG PET/CT before, 2 wk after the start, and 4 wk after the completion of neoadjuvant chemoradiotherapy." | ( Astner, ST; Becker, K; Bundschuh, RA; Dinges, J; Essler, M; Henninger, M; Herrmann, K; Neumann, L; Papp, L; Rosenberg, R; Schwaiger, M; Seyfried, M; Ziegler, SI; Zsótér, N, 2014) |
| "Radiotherapy for advanced rectal cancer is an important treatment to reduce local recurrence." | ( Jung, SH; Kim, JH; Kim, SH, 2014) |
| "Radiotherapy for rectal cancer patients may induce late pelvic complications as time progresses, and irreversible tissue changes due to radiation could disrupt the successful treatment of radiation-related complications." | ( Jung, SH; Kim, JH; Kim, SH, 2014) |
| "Advances in the management of rectal cancer have resulted in an increased application of multimodal therapy with the aim of tailoring therapy to individual patients." | ( Akhurst, T; Heriot, AG; Lynch, AC; Memon, S; Michael, M; Ngan, SY; Warrier, SK, 2014) |
| "A total of 101 low rectal cancer patients receiving preoperative chemoradiotherapy from July 2004 to August 2012 were enrolled." | ( Ishihara, S; Kawai, K; Kitayama, J; Murono, K; Sunami, E; Tsuno, NH; Watanabe, T; Yamaguchi, H, 2014) |
| "Patients with T3/T4 and or N+ rectal cancer (n = 65) were treated with preoperative concomitant boost radiotherapy (55 Gy/25 fractions) associated to concurrent chemotherapy with oral capecitabine." | ( Agolli, L; Bracci, S; De Sanctis, V; Falco, T; Masoni, L; Maurizi Enrici, R; Osti, MF; Valeriani, M, 2014) |
| "In patients with locally advanced rectal cancer treated with neoadjuvant chemoradiation followed by rectal resection, postoperative morbidity is a significant clinical problem." | ( Berkel, AE; Klaase, JM; van der Palen, J; Woutersen, DP, 2014) |
| "Locally advanced rectal cancers are currently treated with neoadjuvant concurrent chemoradiotherapy (CCRT) followed by surgery, but stratification of risk and final outcomes remain suboptimal." | ( Chen, TJ; Hsing, CH; Lee, SW; Lee, YY; Li, CF; Lin, CY; Lin, LC; Sheu, MJ; Wu, TF, 2014) |
| "Brunch Regimen for locally advanced rectal cancer consisting of neoadjuvant chronomodulated capecitabine and concurrent radiation therapy is effective and well tolerated with good safety profile, particularly with regard to the occurrence of hand and foot syndrome, in patients with locally advanced rectal cancer." | ( Akgun, Z; Balik, E; Cipe, G; Gural, Z; Kaytan-Saglam, E; Kilickap, S; Okyar, A; Saglam, S; Yildiz, S; Yucel, S, 2014) |
| "In T3 rectal cancer (RC), preoperative chemoradiotherapy [5-fluorouracil (5-FU-RT)] reduces local recurrences, but does not affect overall survival." | ( Adenis, A; André, T; Azria, D; Borg, C; Bosset, JF; Boudghène, F; Maingon, P; Mantion, G; Mornex, F; Morsli, O; Piutti, M, 2014) |
| "A 60-year-old man with advanced rectal cancer and urinary bladder fistula received preoperative chemoradiotherapy with S-1(120mg/m / 2day)on weekdays and concurrent radiotherapy(65 Gy)." | ( Arakawa, A; Date, K; Kawada, K; Kimura, M; Kuroda, D; Matsushita, H; Nishimura, T; Shimokawa, Y; Soh, M, 2014) |
| "In 30 consecutive rectal cancers that were preoperatively treated with chemoradiotherapy, the clinicopathologic features were correlated with the immunoexpression of AE1/AE3 keratin and carcinoembryonic antigen (CEA)." | ( Bara, T; Gurzu, S; Jung, I; Kadar, Z; Kovecsi, A; Molnar, C, 2014) |
| "Heterogeneity exists in rectal cancer, and we hypothesized that there are subclones resistant to chemoradiotherapy within the cancer mass." | ( Ishihara, S; Kazama, S; Murono, K; Nagai, Y; Nishio, K; Sakai, K; Sunami, E; Tanaka, T; Tomida, S; Watanabe, T, 2014) |
| "A 48-year-old man with colorectal cancer and right inguinal lymph node metastasis had previously undergone radiotherapy and chemotherapy (uracil/tegafur/leucovorin) after a colostomy in another hospital before being referred to us." | ( Aihara, T; Fukuda, S; Iino, C; Mikami, T; Sakamoto, J; Sawaya, M; Tanaka, M; Tono, H; Yamagata, R; Yoshida, K, 2014) |
| "We analyzed 120 rectal cancer patients treated with neoadjuvant pelvic radiotherapy (PRT) with concurrent 5-fluorouracil-based chemotherapy." | ( Apte, A; Deasy, JO; Goodman, KA; Oh, JH; Son, CH; Yang, TJ, 2014) |
| "Their role in chemoradiotherapy for rectal cancers is unclear." | ( Bokey, L; Cheng, C; Chua, W; de Souza, P; Descallar, J; Lee, CS; Lee, MT; Lim, SH; Ng, W; Shin, JS; Solomon, M; Wong, K, 2014) |
| "Preoperative radiotherapy for rectal cancer may affect Leydig cell function." | ( Arver, S; Blomqvist, L; Bottai, M; Buchli, C; Holm, T; Martling, A; Tapper, J, 2015) |
| "Men with rectal cancer stage I-III, treated with radiotherapy and surgery, were eligible, and 40 of 53 men were available for analysis." | ( Arver, S; Blomqvist, L; Bottai, M; Buchli, C; Holm, T; Martling, A; Tapper, J, 2015) |
| "For patients with locally advanced rectal cancer, higher radiation dose may contribute to the improvement of both LC and disease-free survival, without significantly increasing the incidence of acute and long-term complications compared with adjuvant chemoradiotherapy alone." | ( Fu, S; Huang, G; Li, P; Lu, JJ; Peng, L; Tey, J; Xiong, F; Yang, Z; Zhang, Q, 2015) |
| "We report a case of rectal cancer, which was successfully treated with radical resection and neoadjuvant chemoradiotherapy." | ( Ami, K; Ando, M; Arai, K; Gokita, K; Hayasaka, J; Imai, K; Kitazume, A; Kondou, M; Okamoto, E; Shibayama, T; Takagi, K; Tamura, A; Tei, S; Watanabe, A, 2014) |
| "Herein, we present a case of advanced rectal cancer surgically resected after chemotherapy." | ( Kameyama, H; Kobayashi, T; Kosugi, S; Koyama, Y; Minagawa, M; Nogami, H; Sakata, J; Shimada, Y; Suda, K; Wakai, T, 2014) |
| "A 69- year-old man with metastatic rectal cancer received 4 courses XELOX therapy." | ( Egawa, T; Ito, Y; Kemmochi, T; Makino, H; Nagashima, A; Ohkubo, Y; Shimokawa, R; Suzuki, Y; Yamamuro, W; Yoneda, M, 2014) |
| "Our results indicate that rectal cancer patients treated with curative surgery may get survival benefit from avoiding low-dose perioperative dexamethasone." | ( Huang, MJ; Kang, L; Luo, YX; Peng, H; Wang, JP; Yu, HC, 2015) |
| "In recent decades, the management of rectal cancer has been significantly improved by optimizing the surgical treatment with the total mesorectal excision and the development of neoadjuvant radiotherapy with or without chemotherapy." | ( Bednarek, C; Bosset, JF; Cerda, T; Guimas, V; Lepinoy, A; Lescut, N; Schipman, B, 2015) |
| "Ten patients with rectal cancer surgically removed after chemoradiotherapy were included, a subgroup of a randomized trial that compared glutamine and placebo in the prevention of acute radiation enteritis." | ( Ballesteros-Pomar, MD; Calleja-Fernández, A; Cano-Rodríguez, I; Cordido, F; Hernando-Martín, M; Vidal-Casariego, A, 2015) |
| "A 34-year-old man with a history of rectal cancer was receiving oral chemotherapy [tegafur-uracil (UFT) with leucovorin]." | ( Adachi, J; Gotyo, N; Mimura, M; Watanabe, T, 2015) |
| "Patients with locally advanced rectal cancer received sandwich-like neoadjuvant therapy with bevacizumab (induction therapy with bevacizumab and FOLFOX, concurrent chemoradiotherapy with bevacizumab and consolidation chemotherapy with FOLFOX)." | ( Chen, Z; Deng, Y; Huang, Y; Lan, P; Li, W; Peng, J; Ren, D; Wang, J; Wang, L; Xiao, J; Yang, Z; Zheng, J, 2015) |
| "Locally advanced rectal cancer patients who received neoadjuvant chemoradiotherapy following radical resection were retrospectively assessed for tumor response during 2005 to 2014 from the database of colorectal cancer." | ( Du, X; Lin, G; Qiu, H; Wu, B; Xiao, Y; Xu, L; Xue, H; Zhang, G; Zhong, G; Zhou, W, 2015) |
| "Neoadjuvant radiotherapy of rectal cancer represents the current standard of care." | ( Ahmed, BM; AlGizawy, SM; Essa, HH, 2015) |
| "The mainstay of treatment in rectal cancer is neoadjuvant radio chemotherapy prior to surgery, in an attempt to downstage the tumour, allowing for more complete removal during surgery." | ( Bacon, O; Deasy, J; Fay, J; Flanagan, L; Kay, EW; Kehoe, J; Lindner, AU; McNamara, DA; Prehn, JH, 2015) |
| "In most institutions, locally advanced rectal cancer is treated with neoadjuvant chemoradiotherapy followed by surgery 6-8 weeks later, allowing time for tumor response and recovery from chemoradiotherapy-related toxicities." | ( Chang, PK; Chiang, MH; Hsiao, CW; Jao, SW; Lee, CC; Lee, TY; Wu, CC, 2015) |
| "The number of lymph nodes in rectal cancer was correlated with the response of primary rectal lesions to chemoradiotherapy, and was not associated with patient survival." | ( Akahane, T; Aoyagi, Y; Fukushima, Y; Hashiguchi, Y; Hayama, T; Horiuchi, A; Ishihara, S; Matsuda, K; Nakamura, K; Nozawa, K; Shimada, R; Watanabe, T; Yamada, H, 2014) |
| "Ninety-three rectal cancer patients receiving concurrent capecitabine and pelvic intensity-modulated radiation therapy (IMRT) were analyzed." | ( Li, G; Li, K; Liu, K; Wan, J; Zhang, Z, 2015) |
| "Patients with primary resectable rectal cancer were treated with short-course hypofractionated radiotherapy (5×5 Gy) combined with oral rapamycin 1 week before and during radiotherapy, followed by surgical resection." | ( Beets, GL; Belgers, E; Buijsen, J; Clarijs, R; Jansen, RL; Jutten, B; Lambin, P; Lammering, G; Leijtens, JW; Riedl, RG; Sosef, M; van den Bogaard, J, 2015) |
| "Patients with clinical stage II or III rectal cancer undergoing preoperative radiation were randomly assigned to one of four chemotherapy regimens in a 2x2 design: CVI 5-FU or oral capecitabine with or without oxaliplatin." | ( Allegra, CJ; Arora, A; Bahary, N; Beart, RW; Eakle, JF; Evans, LS; Landry, JC; Marchello, BT; Moore, DF; Mullane, MR; O'Connell, MJ; Pitot, HC; Robertson, JM; Roh, MS; Ryan, DP; Sharif, S; Shields, AF; Soori, G; Ward, PJ; Wolmark, N; Wozniak, TF; Yothers, G, 2015) |
| "We describe a case of perforated rectal cancer that became curatively resectable after FOLFOX4 chemotherapy." | ( Fujita, Y; Ishikawa, F; Ito, H; Kamata, S; Nitta, H; Omoto, H; Yamada, C, 2015) |
| "A patient in his 70s was diagnosed with rectal cancer (pT3, pN1, cM0, and pStage IIIa) for which he underwent low anterior resection of the rectum and received adjuvant therapy with UFT/LV." | ( Goya, T; Hanaka, J; Kanamura, S; Nakayama, H; Takahashi, M; Takahashi, S; Wakamatsu, T, 2015) |
| "In this cohort of rectal cancer patients dominated by T4 and advanced T3 cases given sequential oxaliplatin-containing preoperative therapy with acceptable toxicity, high tumour response rates and overall survival were obtained, consistent with both local and systemic effects." | ( Boye, K; Dueland, S; Flatmark, K; Folkvord, S; Giercksky, KE; Grøholt, KK; Hole, KH; Larsen, SG; Ree, AH; Saelen, MG; Seierstad, T; Wiig, JN, 2016) |
| "In patients with rectal cancer who have already received neoadjuvant chemoradiotherapy and undergone curative resection, adding oxaliplatin to 5-FU could prolong OS in patients aged < 73 years and ypN+ category." | ( Chen, XW; Gao, P; Huang, XZ; Ma, B; Song, YX; Sun, JX; Wang, J; Wang, ZN; Zhao, JH, 2016) |
| "Patients with cT2-4 N0-2 M0 rectal cancer treated by standard CRT (54Gy and 2 cycles of 5FU-based chemotherapy) or extended CRT (54Gy and 6 cycles of 5FU-based chemotherapy) underwent sequential PET/CT imaging at baseline, 6 weeks and 12 weeks from radiation completion." | ( Buchpiguel, CA; Fernandez, LM; Figueiredo, MN; Gama-Rodrigues, J; Habr-Gama, A; Perez, RO; Proscurshim, I; São Julião, GP, 2016) |
| "Fifty patients with rectal cancer undergoing neoadjuvant (chemo)radiotherapy and surgery were included in the study." | ( Dvorak, J; Fanta, J; Kubecova, M; Rychterova, V; Voboril, R; Voborilova, J, 2016) |
| "A total of 543 rectal cancer patients who were treated with neoadjuvant chemoradiotherapy followed by radical surgery from January 2007 to December 2011 were reviewed." | ( Cho, YB; Choi, DH; Huh, JW; Kim, HC; Lee, WY; Oh, BY; Park, HC; Park, YA; Park, YS; Yun, SH, 2016) |
| "Patients aged 20-80 with stage II/III rectal cancer undergoing curative surgery without preoperative therapy were randomly assigned to receive UFT (500-600 mg/day on days 1-5, followed by 2 days rest) or S-1 (80-120 mg/day on days 1-28, followed by 14 days rest) for 1 year." | ( Baba, H; Emi, Y; Hamada, C; Ikejiri, K; Kakeji, Y; Kotake, M; Maeda, K; Maehara, Y; Matsuda, C; Matsuda, H; Munemoto, Y; Murata, A; Oki, E; Saji, S; Sasaki, K; Suenaga, T; Yoshida, K, 2016) |
| "Twenty patients with metastatic colorectal cancer underwent FOLFOX chemotherapy from January 2005 to December 2013 at the Niitsu Medical Center Hospital." | ( Kanda, J; Muneoka, K; Sakata, J; Sasaki, M; Shirai, Y; Wakabayashi, H; Wakai, T, 2016) |
| "Here, we present a case of rectal cancer that became curatively resectable after preoperative chemotherapy with mFOLFOX6 plus c-mab." | ( Ariake, K; Doi, T; Takagi, H; Takemura, S, 2016) |
| "In the treatment of male rectal cancer patients, TME combined with arterial infusion with methylene blue can facilitate the distinction of operation scope, which is beneficial to reduce damages to the pelvic nerve, leading to the protection of urinary function and sexual function." | ( He, X; Li, G; Wang, J; Zhang, R, 2016) |
| "Treating metastatic colorectal cancer with anti-EGFR monoclonal antibodies is recommended only for patients whose tumour does not harbour mutations of KRAS or NRAS." | ( Albert, A; Delvenne, P; Hatt, M; Hustinx, R; Jodogne, S; Koopmansch, B; Kustermans, G; Lambert, F; Lovinfosse, P; Polus, M; Seidel, L; Visvikis, D, 2016) |
| "Between 2006 and 2015, patients with rectal cancer, stages I-III, without metastasis, treated with neoadjuvant CRT/CT, who had clinical complete response were included." | ( Chacon, M; Coraglio, M; Dieguez, A; Huertas, E; Iseas, S; Mariani, J; Mendez, G; O'Connor, JM; Pairola, A; Roca, E; Sanchez Loria, F, 2016) |
| "Patients with locally advanced rectal cancer (cT3-4N0 or cTanyN1-2) and synchronous resectable liver-limited metastases (cM1a) were randomly assigned to receive either preoperative treatments of induction CapeOx, followed by chemoradiotherapy with CapeOx (CapeOx-RT) (arm A) or CapeOx-RT alone (arm B)." | ( Cho, H; Hong, YS; Jang, HS; Kim, DY; Kim, JC; Kim, JE; Kim, JH; Kim, KP; Kim, SY; Kim, TW; Lee, MA; Oh, JH; Oh, ST; Yu, CS, 2016) |
| "Data were validated in the rectal cancer cohort treated in the neoadjuvant setting." | ( Bacon, O; Carberry, S; Concannon, CG; Fay, J; Hector, S; Kay, EW; Lindner, AU; McCawley, N; McNamara, DA; Murphy, ÁC; Prehn, JH; Ryan, D, 2016) |
| "Many patients with rectal cancer undergo preoperative neoadjuvant chemoradiation, with approximately 70% exhibiting pathologic downstaging in response to treatment." | ( Carter, JV; Eichenberger, MR; Galandiuk, S; Nelson, B; Netz, U, 2016) |
| "Identification of rectal cancer patients with specific genetic polymorphisms in enzymes involved in 5-Fluorouracil metabolism seems to predict the likelihood of complete or partial pathologic response to preoperative neoadjuvant therapy." | ( Carter, JV; Eichenberger, MR; Galandiuk, S; Nelson, B; Netz, U, 2016) |
| "dMMR rectal cancer had excellent prognosis and pathologic response with current multimodality therapy including an individualized surgical treatment plan." | ( Bednarski, B; Borras, E; Chang, GJ; de Rosa, N; Feig, BW; Krishnan, S; Lynch, PM; Messick, CA; Rodriguez-Bigas, MA; Skibber, JM; Veerapong, J; Vilar, E; You, YN, 2016) |
| "All mid-low rectal cancer patients who underwent low anterior resection with temporary diverting ileostomy after neoadjuvant chemoradiotherapy, between 2006 and 2013, were identified, retrospectively." | ( Duek, SD; Khoury, W; Shalabi, A, 2016) |
| "In patients with high-risk pT1 rectal cancer, adjuvant CCRT after local excision could be an effective alternative treatment instead of revision radical resection." | ( Ahn, SJ; Chung, WK; Jeong, JU; Kim, HR; Kim, YH; Nam, TK; Shim, HJ; Song, JY; Yoon, MS, 2016) |
| "Adjuvant chemotherapy for resected rectal cancer is widely used." | ( Benckert, C; Benedix, F; Bruns, C; Garlipp, B; Gastinger, I; Lippert, H; Otto, R; Popp, F; Ptok, H; Ridwelski, K, 2016) |
| "In this cohort of rectal cancer patients treated with neoadjuvant CRT and TME surgery under routine conditions, adjuvant chemotherapy significantly improved DFS." | ( Benckert, C; Benedix, F; Bruns, C; Garlipp, B; Gastinger, I; Lippert, H; Otto, R; Popp, F; Ptok, H; Ridwelski, K, 2016) |
| "For patients with locally advanced rectal cancer (LARC) treated with preoperation chemoradiation (pCRT), identifying differentially expressed (DE) genes between non-responders and responders is a common approach for investigating mechanisms of chemoradiation resistance." | ( Ao, L; Cai, H; Cheng, J; Gao, Q; Guan, Q; Guo, Y; Guo, Z; Jiang, W; Li, X; Yan, H; Zhang, J, 2016) |
| "Patients with locally advanced rectal cancer (LARC) receiving neoadjuvant chemoradiation (nCRT) can have a complete pathologic response (pCR), and are given postoperative adjuvant chemotherapy (ACT)." | ( Church, JM; Gamaleldin, M; Gorgun, E; Kalady, M; Liska, D; Stocchi, L, 2017) |
| "Patients with ypN0 rectal cancer who have received preoperative chemoradiotherapy can be divided into those who initially were node negative and those whose positive nodes have been sterilized by preoperative therapy." | ( Agostini, J; Benoist, S; Boige, V; Brouquet, A; Dartigues, P; Dumont, F; Goéré, D; Julié, C; Lazure, T; Penna, C; Peschaud, F; Vychnevskaia, K, 2017) |
| "The presence of LNS in ypN0 rectal cancer patients after chemoradiotherapy should not be considered a factor for a poor prognosis." | ( Agostini, J; Benoist, S; Boige, V; Brouquet, A; Dartigues, P; Dumont, F; Goéré, D; Julié, C; Lazure, T; Penna, C; Peschaud, F; Vychnevskaia, K, 2017) |
| "We report 2 cases of metastatic rectal cancer patients who received chemotherapy with FOLFOXIRI plus bevacizumab(Bev)." | ( Aomatsu, N; Hirakawa, T; Iwauchi, T; Morimoto, J; Nagashima, D; Nakazawa, K; Nishii, T; Takeuchi, K; Tei, S; Uchima, Y; Wang, E; Yamakoshi, Y, 2016) |
| "A total of 198 patients with rectal cancer underwent preoperative endoscopic assessments after chemoradiotherapy." | ( Fukayama, M; Hata, K; Ishihara, S; Kawai, K; Kiyomatsu, T; Morikawa, T; Nozawa, H; Watanabe, T, 2017) |
| "In pathological stage N2 rectal cancer patients, administering adjuvant chemotherapy before chemoradiotherapy led to a lower rate of treatment failure, especially with respect to distant metastasis." | ( Fang, H; Feng, YR; Jin, J; Li, N; Li, YX; Liu, XF; Liu, YP; Ren, H; Song, YW; Tang, Y; Wang, SL; Wang, WH; Wang, X; Yu, ZH, 2017) |
| "Patients with rectal cancer treated with chemoradiotherapy and radical surgery from 2003 to 2015 (N = 222) were included." | ( Hata, K; Ishihara, S; Kawai, K; Kiyomatsu, T; Morikawa, T; Nozawa, H; Tanaka, T; Watanabe, T, 2017) |
| "The medical data of 125 rectal cancer patients who received the same neoadjuvant chemoradiotherapy (CRT) followed by surgery were retrospectively collected." | ( Lin, SY; Liu, M; Shan, HB; Wang, HY; Xu, GL; Yang, Q; Zhang, JL, 2017) |
| "We report a case of locally advanced rectal cancer, treated effectively with chemotherapy consisting of mFOLFOX6 combined with radiotherapy." | ( Hashimoto, Y; Hirata, Y; Ishizaki, Y; Kitamura, S; Kuga, Y; Miwata, T; Mouri, T, 2017) |
| "Locally advanced rectal cancer (LARC) is frequently treated with neoadjuvant chemoradiotherapy (NACRT) to reduce the risk of local recurrence and improve survival." | ( Cai, S; Chen, Y; Lin, G; Lu, J; Qiu, H; Sun, X; Wu, B; Xiao, T; Xiao, Y; Xu, L; Zhou, W, 2017) |
| "Patients with unresectable recurrent rectal cancer that progresses after standard and multi-modular treatments are candidates for hypoxic pelvic perfusion." | ( Clementi, M; Fiorentini, G; Guadagni, S; Mambrini, A; Masedu, F; Palumbo, P, 2017) |
| "Outcome of intermediate risk rectal cancer may be improved by the addition of oxaliplatin during 5-fluoruracil concomitant neoadjuvant chemoradiotherapy." | ( Azria, D; Bécouarn, Y; Bedenne, L; Berdah, J; Bouché, O; Conroy, T; de La Roche, G; Denis, B; Doyen, J; Dupuis, O; Etienne, P; François, E; Gérard, J; Gourgou-Bourgade, S; Hennequin, C; Jarlier, M; Juzyna, B; Lledo, G; Mahé, M; Martel-Lafay, I; Mineur, L; Mirabel, X; Seitz, J; Vendrely, V, 2017) |
| "After treating human rectal cancer cell line SW480 with different concentrations of resveratrol, the cellular proliferation was detected by cell counting Kit-8(CCK-8) assay." | ( Lao, LJ; Song, XJ; Xu, J, 2017) |
| "For advanced rectal cancer with involved or threatened mesorectal fascia (MRF), current standard is pre-operative long course chemoradiotherapy (PLCRT) with either capecitabine or 5-fluorouracil (5-FU)." | ( Chiang, CL; Lee, FAS; Lee, SF; Poon, CM; Tung, SY; Wong, FCS; Wong, YW, 2018) |
| "Approximately 30% of locally advanced rectal cancer patients might not benefit from chemoradiotherapy; however, the response to neoadjuvant chemoradiotherapy in these cases is difficult to predict." | ( Chen, G; Lu, SX; Lu, ZH; Pan, ZZ; Wan, DS; Wu, XJ; Zhang, RX; Zhou, ZG, 2017) |
| "In untreated rectal cancer patients, the chymotrypsin-like activity of proteasomes in tumor tissue was 3-fold higher than that in conventionally normal tissue, which is explained by up-regulation of expression of immunoproteasomes and total pool of proteasomes." | ( Afanas'ev, SG; Astakhova, TM; Goncharov, AL; Ivanova, EV; Kondakova, IV; Rodoman, GV; Sharova, NP; Sumedi, IR, 2017) |
| "In patients with locally advanced rectal cancer, high total lesion glycolysis after neoadjuvant chemoradiotherapy is strongly associated with a worse prognosis." | ( Fukayama, M; Ishihara, S; Kawai, K; Koyama, K; Momose, T; Morikawa, T; Okuno, T; Takahashi, M; Watanabe, T, 2018) |
| "Two consecutive FDG PET images of 17 rectal cancer patients undergoing radiotherapy are used to simulate the tumor evolution during treatment." | ( Apeke, S; Boussion, N; Gaubert, L; Lambin, P; Redou, P; Rodin, V; Visvikis, D, 2018) |
| "Eighteen rectal cancer patients with enlarged (≥ 8 mm) LPNs were treated with CRT followed by total mesorectal excision with LPN dissection during 2012-2015." | ( Hata, K; Ishihara, S; Kawai, K; Kiyomatsu, T; Morikawa, T; Nozawa, H; Tanaka, T; Watanabe, T, 2018) |
| "Omission of radiotherapy in rectal cancer is analyzed in the context of historical findings, as well as more recent data describing risk stratification of stage II-III disease, surgical optimization, imaging limitations, improvement in systemic chemotherapeutic agents, and contemporary studies evaluating selective omission of radiotherapy." | ( Czito, B; Martella, A; Palta, M; Willett, C, 2018) |
| "Patients with locally advanced rectal cancer (LARC) who are unfit for chemoradiation (CRT), are often offered short-course radiotherapy followed by delayed surgery (SCRT-delay)." | ( Couwenberg, AM; Hoendervangers, S; Intven, MPW; van Grevenstein, WMU; Verkooijen, HM, 2018) |
| "Patients with rectal cancer were included in the study if they met the following criteria: adenocarcinoma of the rectum, preoperative short-term radiotherapy (5 × 5 Gy), and WHO performance score 0-1." | ( Bednarczyk, M; Bujko, K; Hevelke, P; Kryński, J; Olesiński, T; Pierzankowski, I; Pietrzak, L; Rutkowski, A; Saramak, P; Surowski, P; Szpakowski, M; Zając, L, 2018) |
| "Patients with stages II to III rectal cancer received one cycle of induction chemotherapy and concurrent chemoradiotherapy with XELOX plus bevacizumab." | ( Chang, H; Chen, G; Ding, PR; Gao, YH; Lu, ZH; Pan, ZZ; Wan, DS; Wang, QX; Wu, XJ; Xiao, WW; Yu, X; Zeng, ZF, 2018) |
| "Data on patients with cT3/4 and N+ rectal cancer who were treated in our institution from April 2010 to February 2016 were reviewed retrospectively." | ( Noie, T; Okuyama, T; Ono, Y; Oya, M; Sameshima, S; Tagaya, N; Takeshita, E; Yamagata, Y; Yoshioka, R, 2018) |
| "The management of locally advanced rectal cancer has passed a long way of developments, where total mesorectal excision and preoperative radiotherapy are crucial to secure clinical outcome." | ( Aerts, J; de Mey, S; De Ridder, M; Dufait, I; Engels, B; Feron, O; Gevaert, T; Jiang, H; Verovski, V; Wang, H, 2018) |
| "The German rectal cancer trial CAO/ARO/AIO-04 has shown a significant benefit in 3-year disease-free survival (DFS) of adding oxaliplatin to a standard preoperative 5-fluorouracil (5-FU)-based chemoradiotherapy (CRT) and adjuvant chemotherapy in patients with locally advanced rectal cancer." | ( Arnold, D; Fietkau, R; Fokas, E; Folprecht, G; Ghadimi, M; Grabenbauer, GG; Graeven, U; Hofheinz, RD; Hohenberger, W; Hothorn, T; Kaufmann, M; Liersch, T; Rödel, C; Sauer, R, 2018) |
| "Low and mid locally advanced rectal cancer or T2N0 under risk of sphincter resection underwent chemoradiotherapy followed by total mesorectal excision with curative intent." | ( Bustamante-Lopez, LA; Cecconello, I; Cotti, GC; de Mello, ES; Imperiale, AR; Marques, CFS; Nahas, CSR; Nahas, SC; Pinto, RA; Ribeiro, U, 2018) |
| "We identified 154 patients with rectal cancer treated by elective laparoscopic AR with anastomosis using primary double-stapling." | ( Hara, K; Hotta, M; Iwai, T; Kan, H; Koizumi, M; Okusa, M; Shinji, S; Takahashi, G; Takeda, K; Uchida, E; Ueda, Y; Yamada, T; Yokoyama, Y; Yoshida, H, 2018) |
| "The standard treatment for rectal cancer is neoadjuvant chemoradiotherapy (nCRT) followed by surgery." | ( Akiba, T; Kajiwara, H; Kamei, Y; Miyakita, H; Ogimi, T; Okada, K; Sadahiro, S; Saito, G; Suzuki, T; Tanaka, A, 2018) |
| "Patients with unresectable recurrent rectal cancer that progresses after systemic chemotherapy and radiotherapy are candidates for palliation with hypoxic pelvic perfusion (HPP)." | ( Bencivenga, M; Clementi, M; Fiorentini, C; Guadagni, S; Kusamura, S; Masedu, F, 2018) |
| "Patients with locally advanced rectal cancer (LARC) achieving a pathological complete response (pCR) to neoadjuvant treatment usually have a good prognosis, but only accounted for less than 20%." | ( Jin, M; Lin, Z; Liu, H; Liu, J; Peng, L; Wang, J; Xue, J; Zhang, D; Zhang, T, 2018) |
| "Preoperative radio(chemo)therapy in rectal cancer may irreversibly damage pelvic bone marrow (PBM) and impair the tolerance of subsequent chemotherapy." | ( Michalski, W; Spalek, M; Wyrwicz, L, 2019) |
| "Further, rectal cancer patient samples were analyzed for H3K79me3 levels in order to determine whether it may serve as a potential marker for personalized therapy." | ( Bastians, H; Eggert, J; Gaedcke, J; Grade, M; Henck, JM; Johnsen, SA; Kari, V; Kitz, J; Kosinsky, RL; Kramer, F; Mansour, WY; Najafova, Z; Raul, SK; Spitzner, M; Übelmesser, N; Wegwitz, F, 2019) |
| "Pathologists assess rectal cancers that have responded significantly to neoadjuvant therapy more thoroughly." | ( Avila, K; Chow, OS; Chu, P; Garcia-Aguilar, J; Keskin, M; Patil, S; Shia, J; Smith, DD; Smith, JJ; Widmar, M, 2019) |
| "We reported 2 cases of colorectal cancer receiving neoadjuvant chemotherapy(NAC)with the aim of curative resection or anal preservation." | ( Chiku, T; Hashiba, T; Sano, W; Shinoda, K; Togawa, Y; Yamashita, K, 2019) |
| "A radical rectal cancer surgery was performed 6 to 8 weeks after the simultaneous chemoradiotherapy." | ( Chen, J; Dai, G; Du, X; Feng, L; Jia, B; Liu, H; Liu, Q; Wang, Y; Wen, K; Yang, Y; Zeng, M; Zhu, Y, 2019) |
| "Data from 117 locally advanced rectal cancer patients treated at two Swiss Radiotherapy departments were collected and analyzed." | ( Biggiogero, M; Bourhis, J; De Bari, B; Franzetti-Pellanda, A; Hahnloser, D; Montemurro, M; Ozsahin, M; Saidi, A; Zeverino, M, 2019) |
| "We included patients with rectal cancer who received 4 courses of modified FOLFOX6 (mFOLFOX6) before rectal surgery and examined the postoperative complication rate, the clinicopathological response, and the rate of chemotherapy-related adverse events (UMIN 000012559)." | ( Funakoshi, T; Hattori, M; Hirose, K; Homma, S; Ichikawa, N; Iijima, H; Ishikawa, T; Ishizu, H; Kamiizumi, Y; Kawamata, F; Koike, M; Kon, H; Kuraya, D; Minagawa, N; Murata, R; Nomura, M; Ohno, Y; Omori, K; Sato, M; Takahashi, N; Takeda, K; Taketomi, A; Yokota, R; Yoshida, T, 2019) |
| "Patients with stage II or III rectal cancer who underwent preoperative (chemo)radiotherapy followed by curative surgery (the SCRIPT trial) were included." | ( Hilling, DE; Kapiteijn, E; Marang-van de Mheen, PJ; Meershoek-Klein Kranenbarg, E; Peeters, KCMJ; Tsonaka, R; van de Velde, CJH; van der Valk, MJM, 2019) |
| "We report a case of locally advanced rectal cancer presenting with perforation that was successfully resected after preoperative chemotherapy." | ( Hotei, H; Kuwada, A; Maeda, Y; Murao, N; Sakabe, R; Sakoda, T; Tahara, K; Yoshimura, K, 2019) |
| "Patients with unresectable recurrent rectal cancer that progresses after systemic chemotherapy and radiotherapy may be candidates for palliation with hypoxic pelvic perfusion (HPP)." | ( Bruera, G; Clementi, M; Deraco, M; Fiorentini, C; Fiorentini, G; Gailhofer, S; Guadagni, S; Kusamura, S; Masedu, F; Palumbo, P; Ricevuto, E; Sarti, D, 2019) |
| "A standard therapy for locally advanced rectal cancer (LARC) includes fluoropyrimidine (FP)-based neoadjuvant chemoradiation (nCRT)." | ( Asmis, TR; Cheung, WY; Dudani, S; Goodwin, RA; Gotfrit, J; Marginean, H; Monzon, JG; Raissouni, S; Tang, PA; Vickers, MM, 2019) |
| "Recurrence and chemoresistance in colorectal cancer remain important issues for patients treated with conventional therapeutics." | ( Jang, H; Kim, A; Kim, H; Kim, MJ; Kim, YH; Lee, SB; Lee, SJ; Myung, JK; Park, EH; Park, JH; Park, S; Shim, S, 2019) |
| "Of ypStage III rectal cancer patients who received preoperative RT (5 × 5 Gy) in January 2006-December 2015, those who had ypStage III cancer after preoperative radiation, radical resection, and postoperative chemotherapy were enrolled; excluded patients had ypStage I and II rectal cancer, had double cancer, had synchronous distant metastasis, had local excision, received preoperative chemoradiation, and were lost to follow-up within 1 year after cancer treatment." | ( Chen, CJ; Chin, CC; Huang, CY; Huang, WS; Huang, YC; Kuo, YH; Lai, CH, 2019) |
| "Patients and methods Patients with rectal cancer stage II and III and with at least one high risk factor: T4, presence of extramural vein invasion (EMVI), positive extramesorectal lymph nodes or mesorectal fascia (MRF) involvement were treated with four cycles of induction CAPOX/FOLFOX, followed by capecitabine-based radiochemotherapy (CRT) and two consolidation cycles of CAPOX/FOLFOX before the operation." | ( Anderluh, F; Boc, N; Brecelj, E; Ermenc, AS; Krebs, B; Oblak, I; Omejc, M; Peressutti, AJ; Tuta, M; Velenik, V, 2019) |
| "Progress in rectal cancer therapy has been hindered by the lack of effective disease-specific preclinical models that account for the unique molecular profile and biology of rectal cancer." | ( Becker, SA; Camp, ER; Cross, A; Curl, E; Findlay, VJ; Hill, EG; Hoffman, BJ; Janakiraman, H; Lewin, D; Timmers, C; Wang, C; Warren, GW; Zhu, Y, 2020) |
| "Sixty-one locally advanced rectal cancer patients who underwent a baseline FDG-PET/CT and MRI (T2W + DWI) and received long-course neoadjuvant chemoradiotherapy were retrospectively analysed." | ( Bakers, FCH; Beets, GL; Beets-Tan, RGH; Berbee, M; Lahaye, MJ; Lambregts, DMJ; Maas, M; Min, LA; Roberti, S; Schurink, NW; van Elmpt, W; van Griethuysen, JJM; van Kranen, SR, 2020) |
| "We report a case oflocally advanced rectal cancer with maintained long-term cCR after chemotherapy alone." | ( Abe, T; Hayashi, K; Itoh, S; Kikuchi, I; Kimura, T; Kurihara, Y; Ota, S; Sato, T; Shimbo, T; Wakabayashi, T, 2019) |
| "Patients with rectal cancer using metformin have been associated with improved response to radiotherapy." | ( Asprino, PF; Camargo, AA; Costa, ÉT; Fernandes, JM; Jandrey, EHF; Koyama, FC; Leite, KRM; Perez, RO, 2020) |
| "High-risk rectal cancer patients were randomized to SCRT followed by chemotherapy (6 cycles CAPOX or alternatively 9 cycles FOLFOX4) and subsequent surgery, or long-course radiotherapy (25-28 × 2-1." | ( Bahadoer, RR; Capdevila, J; Cervantes, AMR; de Groot, DJA; Dijkstra, EA; Edhemovic, I; Fokstuen, T; Glimelius, B; Hendriks, MP; Hilling, DE; Hospers, GAP; Kranenbarg, EM; Marijnen, CAM; Nilsson, PJ; Putter, H; Roodvoets, AGH; Ten Tije, AJ; van de Velde, CJH; van der Valk, MJM; van Etten, B, 2020) |
| "Patients with locally advanced rectal cancer will be randomized to receive PCRT followed by TME and adjuvant chemotherapy (arm A) or upfront radical surgery with TME followed by adjuvant FOLFOX chemotherapy (arm B)." | ( Ahn, JB; Baek, JH; Beom, SH; Chang, JS; Hur, H; Jeong, SY; Jung, I; Kim, HS; Kim, NK; Kim, SH; Kim, TI; Koom, WS; Lee, JB; Lee, KY; Lim, JS; Min, BS; Park, S; Shin, SJ, 2020) |
| "Patients with locally advanced rectal cancer (T3/4 and/or LN+) receiving neoadjuvant chemoradiotherapy were enrolled." | ( Fan, J; Li, C; Wan, J; Wang, J; Yang, L; Zhang, H; Zhang, Z; Zhu, J, 2020) |
| "One hundred four non-metastatic rectal cancer patients who underwent pretreatment PET/CT between March 2012 and January 2018 were included in the study." | ( Alper, E; Belge, G; Bilgin, C; Kandemirli, SG; Ozkaya, G, 2020) |
| "The value of adjuvant chemotherapy in rectal cancer is controversial with opinions varying from 'not be used' since randomized trials have not shown significant gains to 'be used as in colon cancer' as the need is the same and colon and rectal cancers are quite similar." | ( Glimelius, B, 2020) |
| "Adjuvant chemotherapy after rectal cancer surgery reduces recurrence risks but the benefit is limited and for most patients not clinically relevant." | ( Glimelius, B, 2020) |
| "Treatment options for locally advanced rectal cancer have continued to consist largely of chemotherapy, chemoradiation, and/or surgical resection." | ( Cho, M; Damle, N; Dayyani, F; Demisse, R; Eng, C; Fakih, M; Gholami, S; Gong, J; Halabi, W; Ji, J; Kim, E; Liu, J; Louie, R; McKenny, M; Monjazeb, A; Oesterich, L; Tam, K, 2020) |
| "Eighty-three patients with rectal cancer, all under neoadjuvant chemoradiotherapy and subsequent surgery, were examined for tissue factors in the biopsy sample." | ( Alahyari, S; Malekzadeh Moghani, M; Moradi, A; Nasiri, M, 2021) |
| "Patients with locally advanced rectal cancers might benefit from treatment in specialized high-volume hospitals." | ( Beißbarth, T; Fietkau, R; Ghadimi, M; Hohenberger, W; Raab, HR; Rödel, C; Sauer, R; Sprenger, T; Staib, L; Tschmelitsch, J, 2020) |
| "An otherwise untreated rectal cancer, progressing over 3 years, regressed after severe toxic dermatitis lasting over one week." | ( Bukovsky, A, 2021) |
| "Watchful waiting in patients with rectal cancer with complete clinical response after chemoradiation therapy has gained increased popularity to avoid morbidity and mortality associated with surgery." | ( Brock, C; Christensen, P; Gram, M; Haas, S; Krogh, K; Laurberg, S; Lundby, L; Mohr Drewes, A; Møller Faaborg, P, 2020) |
| "Patients with rectal cancer solely with chemoradiation therapy (n = 13) a median of 3." | ( Brock, C; Christensen, P; Gram, M; Haas, S; Krogh, K; Laurberg, S; Lundby, L; Mohr Drewes, A; Møller Faaborg, P, 2020) |
| "Chemoradiation therapy for distal rectal cancer causes abnormal cortical processing of both anal and rectal sensory input." | ( Brock, C; Christensen, P; Gram, M; Haas, S; Krogh, K; Laurberg, S; Lundby, L; Mohr Drewes, A; Møller Faaborg, P, 2020) |
| "A 58-year-old woman diagnosed with rectal cancer received surgery and chemotherapy 17 years ago, and since then, she has been tumor-free." | ( Kuang, A; Shen, G, 2021) |
| "We present a case of locally advanced rectal cancer(LARC)treated by robot assisted intersphincteric resection(ISR)and lateral lymph node dissection(LLND)after neoadjuvant chemotherapy(NAC)." | ( Hata, T; Imada, A; Kagawa, Y; Katsura, Y; Kawai, K; Kusafuka, H; Masuzawa, T; Murakami, K; Murata, K; Omura, Y; Sakamoto, T; Takeda, Y; Takeno, A, 2021) |
| "The patient had locally advanced rectal cancer with widespread contact with the sacrum, and preoperative radiochemotherapy (S-1 100 mg/day plus radiotherapy 50 Gy/25 Fr)was performed." | ( Ichikawa, J; Koreeda, N; Nishiki, M; Noritomi, T; Okamoto, T; Ryu, S; Sannomiya, H; Sato, K; Shin, Y; Yamana, I; Yanagisawa, J; Yoshida, Y, 2020) |
| "Both LRC and DFS of rectal cancer patients treated with HART vs." | ( Dębosz-Suwińska, I; Galwas-Kliber, K; Idasiak, A; Mrochem-Kwarciak, J; Rajczykowski, M; Stobiecka, E; Suwiński, R; Zeman, M, 2021) |
| "In time- and resource-constrained rectal cancer units in developing countries, short-course radiotherapy should be the standard of care." | ( Akhtar, N; Bhatt, MLB; Chakrabarti, D; Gupta, R; Gupta, S; Kumar, V; Qayoom, S; Rajan, S; Srivastava, K; Verma, M, 2021) |
| "Male patients with ARS 1 month after rectal cancer surgery or ileostomy reversal were enrolled and randomly assigned (1 : 1) to 5 μg of ramosetron (Irribow®) daily or conservative treatment for 4 weeks." | ( Jeong, SY; Kim, MJ; Kwon, YH; Lee, DW; Lee, MA; Moon, SH; Park, JW; Park, KJ; Ryoo, SB, 2021) |
| "He underwent surgery for early-stage rectal cancer and received adjuvant chemotherapy with oral capecitabine." | ( Eminler, AT; Hacibekiroglu, I; Karacaer, C; Koksal, AS; Toka, B; Tozlu, M; Uslan, MI, 2022) |
| "Locally advanced rectal cancer is typically treated with chemoradiotherapy followed by surgery." | ( Al Diffalha, S; Alexander, KL; Bellis, SL; Hardiman, KM; Irwin, R; McLeod, MC; Nearing, M; Smithson, M; Smythies, LE; Williams, G, 2022) |
| "Following the diagnosis of RS rectal cancer with muc, pT4a, N3(14/15), M1c, P1, pStage Ⅳc, RAS/BRAF: wild type, treatment was initiated with mFOLFOX6 plus panitumumab(Pmab)." | ( Eguchi, S; Fukuoka, T; Iseki, Y; Lee, S; Miki, Y; Muguruma, K; Nagahara, H; Ohira, M; Shibutani, M; Tamura, T; Tanaka, H; Toyokawa, T; Tsujio, G; Yashiro, M; Yoshii, M, 2021) |
| "The standard treatment of stage II-III rectal cancer is preoperative chemoradiotherapy (CRT), followed by total mesorectal excision (TME)." | ( Kim, SH; Lee, JH; Song, JH; Um, JW, 2022) |
| "Treatment of locally advanced rectal cancer includes chemoradiation and surgery, but patient response to treatment is variable." | ( Cho, CS; Choi, EK; Ganguly, A; Hardiman, KM; Irwin, RK; Leopold, J; McLeod, MC; Pepple, A; Smithson, M; Willey, CD; Williams, G, 2022) |
| "In patients with rectal cancer who underwent preoperative CCRT, neoadjuvant therapy of metformin before CCRT was significantly associated with good tumor response." | ( Han, J; Han, SH; Kim, H; Kim, JH; Lee, JW, 2022) |
| "It is used for metastatic colorectal cancer (mCRC) treatment." | ( Alandağ, C; Karaman, E; Yüce, E, 2022) |
| "Patients with metastatic colorectal cancer who switched from capecitabine to S-1, given as monotherapy or in combination with other agents, were identified in a Dutch prospective cohort study (2016-2021)." | ( Kwakman, JJM; Mol, L; Punt, CJA, 2022) |
| "Stage II and III rectal cancer patients were randomized to receive neoCRT with either capecitabine (group 1) or 5-Fu and leucovorin (group 2) concomitant to long-course radiotherapy." | ( Araujo, RO; Ferreira, CG; Guaraldi, S; Linhares, E; Martins, I; Thuler, LC; Torres, C; Valadão, M; Victorino, AP; Vieira, FM, 2022) |
| "Patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy followed by surgery were included in the study." | ( Bertrand, N; Bridoux, M; Le Deley, MC; Mirabel, X; Simon, N; Sylla, D; Turpin, A, 2023) |
| "After proton beam therapy, the rectal cancer was eradicated at colonoscopy, and she was referred for surveillance." | ( Aizawa, M; Endo, S; Isohata, N; Lefor, AK; Nakajima, Y; Nemoto, D; Togashi, K; Utano, K, 2022) |
| "Locally advanced rectal cancer (LARC) has a high incidence of local and distant relapse even after adequate treatment." | ( Azmy, AM; Elhawi, ME; Ghali, RRY; Gobran, NS; Shakweer, MM; Soliman, DA, 2022) |
| "Twenty rectal cancer specimens were collected after preoperative radiotherapy." | ( Bai, C; Broens, P; Furnee, E; Gao, X; Hao, L; Liu, L; Lou, Z; Sun, G; Trzpis, M; Ye, X; Zhang, H; Zhang, W; Zheng, K, 2022) |
| "We herein report a rectal cancer patient who underwent percutaneous transhepatic stoma variceal embolization (PTO) and partial splenic artery embolization (PSE) for stomal variceal bleeding and splenomegaly due to portal hypertension caused by SOS after CAPOX therapy." | ( Hasegawa, K; Ihara, K; Mizukami, S; Ohara, M; Sawada, K; Shonaka, T; Sumi, Y; Takeda, T; Tani, C; Tanino, M, 2023) |
| "The accuracy of T2 and T3 staged rectal cancers was more likely to be correct (compared with T1 cancers) with the administration of IV hyoscine butylbromide." | ( Gelber, N; McMurrick, P; Oliva, K; Ranchod, P; Taylor, A; Wang, WC; Wilkins, S; Yap, R, 2023) |
| "The treatment of colorectal cancer (CRC) has evolved and become more personalized during the past several years." | ( Damato, A; Dottorini, L; Ghidini, A; Ghidini, M; Iaculli, A; Luciani, A; Petrelli, F; Tomasello, G, 2023) |
| "Not all RAS wild-type metastatic colorectal cancer (mCRC) patients experience the same benefit from anti-epidermal growth factor receptor (EGFR) treatments." | ( Araz, M; Artaç, M; Demirkıran, A; Demirkıran, D; Eryılmaz, MK; Karaağaç, M; Kılınç, F; Koçak, MZ; Korkmaz, M, 2023) |
| "He had a history of rectal cancer, which invaded into the urinary bladder and ileum and was treated with chemotherapy, radiotherapy, resection of the rectum, colostomy, and ileal conduit construction." | ( Katayama, T; Takahashi, K; Yahara, O; Yamada, T, 2023) |
| "Standard treatment of locally advanced rectal cancer (LARC) was neoadjuvant chemoradiotherapy (CRT), followed by total mesorectal excision (TME)." | ( Bai, S; Cai, P; Chang, H; Chen, G; Gao, Y; Liu, S; Luo, H; Pan, Z; Wang, Q; Wang, X; Wu, X; Xiao, W; Ye, Y; Yu, H; Zeng, Z; Zhuang, Y, 2023) |
| "For patients with locally advanced rectal cancer choosing between neoadjuvant FOLFOX and 5FUCRT, the distinctive PRO profiles inform treatment selection and shared decision making." | ( Basch, E; Chang, G; Colgrove, B; Denicoff, A; Dueck, AC; Farma, J; George, T; Ginos, B; Gollub, M; Mamon, H; Mazza, GL; Meyerhardt, JA; Minasian, L; Mitchell, SA; Musher, B; O'Reilly, E; Rogak, L; Saltz, L; Schrag, D; Shi, Q; Thanarajasingam, G; Venook, A; Weiser, M, 2023) |
| "In patients with locally advanced rectal cancer who were eligible for sphincter-sparing surgery, preoperative FOLFOX was noninferior to preoperative chemoradiotherapy with respect to disease-free survival." | ( Al Baghdadi, T; Basch, E; Chang, GJ; Colgrove, B; Dueck, AC; Farma, JM; George, TJ; Goldberg, J; Gollub, MJ; Goodman, KA; Gordon, V; Kennecke, HF; Mamon, HJ; McWilliams, RR; Meyerhardt, JA; Montemurro, M; Musher, BL; Nelson, GD; O'Reilly, EM; Saltz, LB; Schrag, D; Shergill, A; Shi, Q; Venook, AP; Weiser, MR, 2023) |
| "Data from patients with rectal cancer treated with radical resection were collected from Nanfang Hospital between January 2014 and June 2021." | ( Cheng, J; Hu, Y; Ji, H; Li, Q; Li, Z; Liu, X; Lu, J; Wang, S; Wu, X; Yan, J; Zhu, W, 2023) |
| "For patients with rectal cancer and treated with neoadjuvant chemoradiotherapy, metformin administration in diabetic patients increased the pathological response on tumor-regression grade and T downstaging." | ( Chern, YJ; Hsu, YJ; Lai, IL; Tsai, WS; Wu, MY; You, JF, 2023) |
| "Patients with locally advanced rectal cancer treated with total neoadjuvant therapy (TNT) may achieve organ preservation without a compromise to oncologic outcomes." | ( Garcia-Aguilar, J; Kim, JK; Lin, ST; Omer, DM; Qin, LX; Saltz, LB; Thompson, HM; Valdivieso, SC; Verheij, FS; Wu, AJ; Yuval, JB, 2024) |
| "Some patients with advanced rectal cancer develop cancer pain even though they are sufficiently treated with opioids or palliative radiation therapy." | ( Iriuchijima, N; Kato, H; Kimura, A; Morinaga, N; Morishita, A; Ogata, K; Okuyama, T; Sato, J; Takase, T; Tsukagoshi, H; Wada, W; Yoshikawa, N, 2023) |